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Implantable cardioverter- defibrillators (ICDs) have become widely applied in both 
ischaemic and non-ischaemic aetiologies to reduce the incidence of sudden 
cardiac death (SCD). The challenge has been to improve defibrillation efficacy, 
prolong battery longevity, and to minimise the device footprint. The pursuit of a 
painless therapy has motivated the development of anti-tachycardia pacing 




To explore novel applications for both modes of ICD therapy:  
1. To evaluate measures that enhance the efficacy of defibrillation using an 
animal based model. 
2. To assess the usefulness of painless ATP therapy as a means of pacing 
for Supraventricular Tachycardia - Ventricular Tachycardia (SVT-VT) 
discrimination and to assess the burden of inappropriate therapies (ITS) in 




The defibrillation studies were performed in a porcine model given its 
resemblance to the human heart and its resilience to repeated ventricular 
fibrillation inductions (VF) and defibrillations. A novel sequential preshock 
waveform was assessed in a prototype serial capacitance device. Single and 
multi-electrode defibrillation vectors were evaluated in intra-cardiac, 
subcutaneous (SQ), and intra-pericardial configurations. The burden of ITS and 
the factors improving detection were assessed. Anti-tachycardia pacing was used 
to evaluate therapies in this patient cohort. The diagnostic utility of the post 
pacing interval (PPI) after failed ATP episodes was then investigated to help 















A monophasic preshock was found to be adjunctive together with a standard 
biphasic waveform; presumably because of the prolongation of the post shock 
iso-electric window. A multi-site Right Ventricle (RV) defibrillation strategy was 
shown to improve measures of defibrillation outcome. A single antero-posterior 
SQ defibrillation vector was as efficacious as a multiple SQ array configuration; 
however, an additional parasternal anode was less effective. Percutaneous 
delivery of an intra-pericardial defibrillation electrode is technically feasible and is 
effective for both a pace/sense and defibrillation strategy. Despite advances in 
ICD development, ITS occurred in 15% of cases studied. Failed ATP resulted in 




Defibrillation efficacy may be enhanced by the addition of a monophasic 
preshock. Marginal benefit was demonstrated with the addition of a second RV 
defibrillation electrode. An SQ antero-posterior transthoracic shock vector was 
optimal in a transthoracic defibrillation strategy and an intra-pericardial 
defibrillation electrode could be percutaneously positioned and used effectively to 
defibrillate.  
 
The PPI after failed ATP is a useful discriminator of AF/AT from VT and has 
diagnostic potential in single chamber devices. 
The burden of ITS is reduced with dual chamber ICDs, programming advanced 
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The first human implantation of a defibrillator was reported by Mirowski and 
colleagues in 19801. Since then, there have been remarkable changes that have 
advanced the indications for implantable cardioverter-defibrillators (ICD).  
Three major technological advances that have contributed to the enhanced 
clinical application of the ICD are the use of transvenous leads, an active Can 
(the active housing of the ICD electrode) and the biphasic defibrillation 
waveform2. 
Despite great advances with defibrillator design and development, the optimal 
defibrillation waveform to minimise energy drain on the battery and to achieve a 
painless shock remains elusive. 
This thesis discusses the current understanding of the mechanisms and theories 
of ventricular fibrillation (VF) as well as the concepts of defibrillation and anti-
tachycardia pacing (ATP). The experimental chapters that follow advance these 
concepts by expanding on waveform design and novel vectoral arrangement 
using a porcine model. The modality of ATP is explored in the clinical chapters.  
The use of animal subjects for these experiments is required given that 
defibrillation threshold (DFT) testing requires multiple VF inductions and 
defibrillations that may result in neurological and cardiac injury3;4. 
The clinical trend is to avoid defibrillation testing as a routine but when it is 












However, DFT testing remains the only method to titrate the minimum level of 
energy required to defibrillate fibrillating myocardium successfully. Defibrillation 
threshold testing, therefore, still has relevance in a research capacity.  
The development of 40J high-energy devices may seem to negate the need to 
find ways to reduce DFTs. However, deleterious effects have been identified with 
higher energy shocks. These include electroporation cell injury, altered action 
potential waveforms and duration, resting membrane potential disruption, 
increased pacing thresholds, loss of excitability, induction of after-depolarisations 
that may be pro-arrhythmic, myocardial stunning, haemodynamic alterations 
including progression to heart failure, and psychological trauma5. This validates 
further research into reducing defibrillation energies. 
Anti-tachycardia pacing is an effective and painless component of therapy in 
modern ICDs. I have addressed ATP as a form of pacing for supraventricular 
tachycardia (SVT) and ventricular tachycardia (VT) discrimination and identified 
the post pacing interval (PPI) after ATP as having diagnostic potential .This 
thesis comprehensively addresses both forms of ICD therapies and takes a novel 
outlook on their roles and application6. 
Current device algorithms have a sensitivity approaching a 100% in identifying 
ventricular arrhythmias7. However, inappropriate therapies (ITS) remain a 
significant problem8. The burden of ITS is examined here in a typical clinical 
cohort as well as factors related to device programming that help ameliorate ITS. 












development and sets the tone for possible further investigation into the PPI as a 
programmable diagnostic parameter.  
Our knowledge of the mechanisms of ventricular fibrillation and defibrillation is 
still incomplete. In the following introductory sections I will describe the current 
state of knowledge around concepts related to the basic science experiments in 
this manuscript. These experiments are intended to build on our current 
understanding of defibrillation waveforms, polarity, and cellular response to high 
voltage energy delivery. 
Aspects of ICD structure and design will be elaborated on to encapsulate the 
challenges faced in order to minimise device volume while promoting battery 
longevity. 
A basic description of high voltage lead design is also necessary as this is 
relevant to the several chapters related to lead position and manipulation of leads 
and arrays in order to alter defibrillation vectors in an attempt to enhance 
defibrillation efficacy. 
The clinical studies relevant to ICD treatment is also briefly highlighted with 
relevance to landmark trials that demonstrate survival benefit and this brings into 














Advancements in ICD therapy include the development of ATP, and the clinical 
trials that have led to this technology are also mentioned. A basic understanding 
of the concept of ATP is established before I embark on the experimental 












1.1 Concepts Related to Defibrillation and Defibrillation Testing 
Theories about the Mechanisms of Defibrillation 
Concepts of defibrillation have evolved from the Dudel model (1968), which 
called for complete myocardial paralysis, and Wiggers (1930s) who formulated a 
Total Extinction Hypothesis. Both implied that complete annihilation of 
fibrillating myocardial wavefronts was required to terminate VF9. 
 Mower et al. and Zipes et al. contradicted these theories with a Critical Mass 
Hypothesis that suggested that in order to terminate VF a critical mass of 
myocardium was required to effect defibrillation. This was proven in a canine 
model by infusing a potassium solution into the coronary arteries in a sequential 
fashion until VF was terminated10. 
Chen et al. postulated that there is a vulnerable period during which VF is 
stopped but is re-initiated by sub-therapeutic shocks. Beyond a particular 
threshold, defibrillation does not re-initiate VF. This is referred to as the Upper 
Limit of Vulnerability11;12. 
The Iso-electric Window 
An apparent period of electric quiescence has also been recognised to occur 
after delivery of a high voltage shock. This is referred to as the iso-electric 
window (ISW). This window lasts for a variable duration ranging between 40–












studies and therefore excludes artefact from blanking or post shock saturation of 
conventional electrical mapping systems as an explanation for this observation14. 
Sub-threshold propagated graded responses, as well as undetectable micro re-
entry have been postulated to occur during this period with re-initiation shown to 
occur preferentially at epicardial locations and within the intra-myocardial layer of 
the left ventricle (LV)15;16. 
Supposedly, re-initiation of VF after the ISW may be on the basis of triggered 
activity in the form of early after depolarisation. Hyperpolarisation of the cellular 
membrane with a sequential and timely delivered shock into the ISW may 
possibly suppress the after depolarisation. This concept may explain why 
preshock delivery may lower DFTs and relates to the first experimental chapter in 
this thesis (Chapter 4). 
Defibrillation Testing 
Acute defibrillation testing at implantation has traditionally been employed to test 
the efficacy of the circuit. However given advancements in modern lead and 
device design, it has become apparent that such practices may be obsolete and 
a more selective approach to defibrillation threshold testing should be taken17. 
Protagonists for avoiding DFT testing argue that DFT testing increases patient 
morbidity and does little to benefit patient care with an already known high 
efficacy of modern ICDs18. This argument, however, is not relevant to the 












determining the minimum defibrillation energy required. This was also carried out 
in an animal model, and not on human subjects, thereby eliminating the ethical 
factors relating to myocardial injury and psychological trauma. The defibrillation 
threshold is defined as the lowest energy that successfully terminates VF. The 
threshold plotted against probability of success translates into a sigmoidal graph. 
The DFT is reflected as the probability of success at a given energy and is 
quoted in terms of percentage; e.g. DFT50 indicates 50% of successful shocks 
for the given energy discharge (ED) and ED90 represents 90% successful 
shocks at this portion of the curve10 (Figure 1.1.1). 
Defibrillation Testing Algorithms 
1. Binary search – this starts at an intermediate level of energy and employs an       
up/down strategy to derive the lowest energy of defibrillation.  
2. Bayesian search – this closely resembles the binary search format but uses 
voltage output for defibrillation testing. 
3. Step-down protocols – the first energy is set at 10 J below the maximum 
energy output of the device. If successful, the energy is sequentially reduced until 
a minimum point is reached which fails to defibrillate.  
4. Single energy success – this method minimises the testing, reducing total 
duration in VF and is a favoured clinical option as it limits the number of 
inductions and shocks during testing. Typically, an output 10 J less than the 
maximal energy of the device is chosen for defibrillation. This may be repeated 
given the probabilistic nature of defibrillation. Thereafter, the device is 




















Figure 1.1.1  
Graphic representation of shock energy against % of successful 
defibrillation attempts. Graph B represents a higher energy requirement for 
defibrillation success. 







































Clinical Factors Affecting Defibrillation 
Efficacy of defibrillation may be influenced by factors related to the substrate and 
then by the ICD system itself19. 
Substrate related factors include 
1. Hypoxia 
2. Ischaemia  
3. Hyperkalaemia 
4. Increased myocardial mass, either due to hypertrophy or dilatation20 
5. Increased body mass index 
6. Pneumothorax and pericardial effusions – these create parallel currents 
shunting energy away from the myocardium21  
7. Antiarrhythmic drugs – Amiodarone has been recognised to increase DFTs, 
however, this was shown to be marginal and probably not clinically relevant in 
the OPTIC trial22-24 
8. Multiple defibrillations 
9. Prolonged VF duration 
Factors Related to the ICD System 
1. Poor lead position 
2. Increased high voltage impedance  
3. Poor current distribution (Low impedance from current shunting) 
4. Current shunting from retained guide wires/leads (passive electrode effect25)  












Thus, in a clinical setting, recognition of factors that may impair defibrillation may 
then be the criteria to select patients for defibrillation testing in order to insure 
safety margins rather than opting for routine DFTs. 
Measures Employed to Improve Defibrillation Thresholds 
Reversing the polarity of the shock vector is usually the first adjunctive measure 
in a clinical setting, as it requires no further intervention, but is a programmable 
option in the ICD. Repositioning of the right ventricle (RV) endocardial lead and 
using the sensing and pacing parameters as a surrogate for optimal electrode 
and tissue contact is also a consideration. Thereafter, addition of extracardiac 
electrodes, either subcutaneously or transvenously, are relied upon to provide 
alteration in the shock vector and to increase the amount of muscle mass that is 
interposed within the defibrillation circuit, e.g. the addition of a separate 
transvene superior vena cava (SVC) coil placed within the azygous or left 
subclavian veins26;27. The proximal coil (integrated SVC coil) in dual coil 
defibrillator leads should also be optimally situated outside the right atrium (RA) 
at the left subclavian level and SVC junction. This SVC component of these dual 
coil leads can be programmed in or out of the circuit as can the active Can 
electrode of the ICD by some manufacturers. 
Apart from altering the shock vector, varying the phase duration of waveforms 
has also been shown to improve DFTs28;29. 
The addition of subcutaneous arrays may also be considered in addition to the 












intervention30. Still, it may be the preferred option if vascular access is obstructed 
by stenoses, or in order to avoid intravascular and intra cardiac lead placement in 
children. 
In addition, manipulation of anti-arrhythmia agents may be a clinical 
consideration, such as removal of Amiodarone, which raises DFTs, or the 
addition of Sotalol and Dofetilide, which lower DFTs31. 
The initial measures derived from clinical practice mentioned here relate to 
waveform alteration and defibrillation vectoral changes. These provided the 
motivation and basis for the hypothesis generation behind the defibrillation-based 












1.2 The Implantable Cardioverter-Defibrillator, Leads, and Implantation 
Techniques  
Initial ICD designs were large, weighing 195–235 g, and required abdominal 
implantation under the rectus sheath and connection to epicardial defibrillator 
patches requiring transthoracic placement. These have now markedly reduced in 
size but have increased in functionality. 
Complex algorithms are now commonplace to aid diagnostic differentiation of 
rhythms and to minimise the risk of ITS. 
Ventricular tachyarrhythmia therapies include both high rate overdrive ATP of 
various permutations, as well as the programmable shock discharge. 
Modern ICDs now may have a volume of 30–39 cm3 and weigh merely 66–84 g. 
Implantation is either pre- or sub-pectoral with a transvenous closed-chest 
implantation technique that can be performed under local anaesthesia and 
conscious sedation. 
Batteries 
The majority of the bulk of the devices was contributed by the size of the battery 
and capacitors (Figure 1.2.1). Two batteries were used in the past; a Lithium-
based composite (e.g. Li Iodide) required for the pacemaker function and internal 
circuitry, and a silver vanadium oxide (SVO) battery to charge the capacitors for 












Lithium silver manganese vanadium oxide is now used. Two batteries in series 
help prolong the device life, but increase overall size32. Current devices have 
been significantly reduced in size with hybrid single battery technology that 
provides greater longevity extending out from 2–8 years depending on usage. 
The stored energy of original batteries was in the order of 8000J. Current 
batteries store a charge of 18000J. Two of these batteries are usually configured 
in series, although newer devices now employ a single hybrid battery. This single 
battery is required to support both the anti-tachycardia and bradycardia functions, 
telemetry and discriminator circuitry with an anticipated longevity of 
approximately 8 years. 
A beginning of life charge of 3.2 V is typical and elective replacement indicator is 
reached at 2.6 V. This allows elective scheduling of pulse generator replacement 
















Figure 1.2.1  
An internal view of the structure of a typical ICD  
(Reproduced from Improvements in 25 Years of Implantable Cardioverter 













Since the battery alone cannot build up sufficient charge to deliver high energy 
shocks, capacitors are required to store and release a charge into myocardial 
tissue. Aluminium based electrolyte capacitors have been used because of their 
ability to charge to energies of 30–40 J from a total battery charge of 3.2–6.4 V 
over a rapid period of 10–30 seconds.  
A reduction in capacitor size is advantageous since smaller ICDs allow ease of 
implantation and concealment at the implant site. However, smaller capacitors 
require a higher peak voltage improving defibrillation safety margins. Capacitors 
are now smaller in the 60–90 µF range, which parallels the time membrane 
constant for human cardiac cells, as opposed to the 140µF capacitors used 
previously in older ICDs. This has shown a modest reduction in DFTs.  
Amplification of Signals 
Sensed signals from the device are processed through high and low pass filters 
that help remove extraneous noise so that a mid-range of signal is made 
available to discriminatory algorithms. There is an overlap between atrial and 
ventricular events, as well as depolarisation and repolarisation phenomena, 
including sensed myopotentials or noise from the device system itself that make 















Wireless communication with the ICD and its programmer is now available in a 
Real-time telemetry format. These signals are sent as radiofrequency signals or 
a pulsed magnetic field. The radiofrequency signal is pulsed and encoded at a 
particular frequency that is specific for each manufacturer33. This prevents error 
programming of other devices and eliminates the influence of environmental 
sources. It also makes manufacturer signals specific for device analysers. 
Microprocessors 
The microprocessor in an ICD or pacemaker has to be engineered to limit its 
battery usage, whereas a microcomputer has potentially endless power available 
from an AC source. The implantable pulse generator (IPG) may contain both 
ROM and RAM (read only and random access memory, respectively) although 
exclusive RAM based generators limit production costs and allow flexibility in 
terms of software upgrades or troubleshoot patches that may eventually arise. 
ICD Lead Technology 
Modern leads are multi-lumen, consisting of both a pace/sense as well as high 
voltage components for defibrillation. They may be dual coil or single coil and 
contain passive (tined ends) or active fixation mechanisms (a spiral screw at the 












tip electrode and RV defibrillation coil, or true bipolar which uses the tip electrode 
and a proximally located, separate ring electrode. 
The outer coating may consist of silicone, polyurethane or fluoropolymers, which 
are all biocompatible. More recently, a blend of polyurethane and silicone has 
been employed or a polyurethane outer coating which reduces friction, improves 
handling at implantation and apparently enhances lead durability as per 
manufacturer claims34. Fibrotic adhesions are also reduced and this is 
advantageous during ICD and lead revisions or replacements. It also potentially 
reduces the incidence of venous occlusion. 
Implantation Techniques  
Although a general anaesthetic is used by some centres, defibrillator implantation 
is also performed under conscious sedation. A transvenous technique is 
favoured from either a left or right pre-pectoral or sub-pectoral site. Both sites 
have been shown to be efficacious although right sided implants may have 
higher DFTs33;35. This facilitates rapid recovery and does not result in increased 
morbidity or discomfort to the patient. The defibrillator lead is implanted at an RV 
apical location with the SVC coil (in dual coil leads) positioned in the SVC to the 
right of the vertebrae, but superior to the right atrium. 
Surgical transthoracic placement with epicardial patches or a hybrid technique 
with endocardial and epicardial leads is an option. Because of the size of 












The use of a dual coil defibrillator lead has not been shown conclusively to be 
superior to a single defibrillator coil lead36. 
In the subsequent experimental chapters, I have performed studies in close 
chested pigs, primarily using a transvenous lead implantation technique except 
for transthoracic and intrapericardial lead placements. The RV apical electrode 
position was also used in the control experiments with the active Can electrode in 
a left chest, subcutaneous pocket to resemble a typical clinical implantation. The 
SVC coil was usually excluded from the circuit as this lead could not always be 












1.3 Shock Waveforms and Cellular Response. 
Shock Waveforms 
The shock waveforms can affect defibrillation efficacy as well influence the extent 
of cellular damage caused by the transmembrane potential induced by shock. 
This is referred to as electroporation and is explained in detail later in this 
introduction.  
Several waveforms have been developed from the basic monophasic square 
wave and include: a damped sine wave, truncated descending waveform, and a 
truncated exponential ascending/ramp waveform (Figure 1.3.1)10. 
The shape of the waveform determines the peak voltage and the energy 
achieved which impacts on stimulation thresholds while the phase duration i.e. 
time constant also determines the efficacy of the waveform. A time constant of 
2.8–4 ms has been determined to be optimal for internal defibrillation while 5 ms 
is optimal for external defibrillation. 
The fast rise to peak voltage after a capacitor discharge results in a typical 
leading wavefront spike. If the rate of rise of this wavefront is slowed, this results 
in a rounding of the peak. This variation has been shown to result in improved 
defibrillation efficacy in biphasic and triphasic waveforms37;38. 
The effect of a shock discharge on myocardial tissue is both stimulatory and 
defibrillation. To defibrillate myocardium successfully, a shock has to alter the 












affect the transmembrane potential of a certain number of cells adjacent to the 
electrode.  
The first phase of a biphasic waveform serves to alter transmembrane potential 
in order to minimise heterogeneity of charge across several cells while the 
second phase restores transmembrane potential and obliterates virtual 
electrodes39. 
Despite the evidence from prior studies, the options for manipulation of 
defibrillator waveforms remain limited to polarity reversal and pulse wave 
duration in modern ICDs. These remain largely non-programmable. 
In the first two chapters of this thesis, I evaluated delivery of preshock as a 
programmable option in a serial capacitance prototype defibrillator. This 
prototype affords additional options for waveform manipulation and optimisation 
in an effort to improve defibrillation efficacy. 
 
The Burping Theory39;40 
The first phase of a biphasic shock extends the refractory period of ventricular 
myocytes, while the second phase removes excess charge from the remaining 
cells. This is beneficial for marginally stimulated cells that have a delayed 
potential. Myocardial cells in the vicinity of an electrode and in areas bordering 














This refers to the acute injury sustained by myocyte cell membranes from 
delivery of a high voltage electric field. The result causes increased permeability 
of the cell membrane to ionic efflux in a regional manner. This is a transient 
phenomenon and is reversed during the second phase of a biphasic shock. The 
polarity of shock delivery plays a role in the degree of cell membrane injury but 
this data is inconsistent in studies43;44. 
Virtual Electrode 
The physical electrode charge induces a similar charge on the surrounding 
myocytes up to a variable diameter depending on the strength of the field. 
Therefore a virtual anode will surround the physical anodal electrode because of 
migration of the oppositely charged ions to cluster around the electrode at the 
tissue interface. 
The virtual electrode effect produced during defibrillation on myocytes influences 
the efficacy of shocks and depolarised regions41;42. 
The Effect of Polarity  
Previously, the RV electrode was programmed as the cathode (-) and this was 
regarded as normal polarity. This, however, has been shown to cause expanding 
wavefronts with delivery of shocks, dissipating into the surrounding fibrillating 
myocardium and is thus potentially arrhythmogenic. With programming of the 












reducing their stimulatory effect. Kroll et al. demonstrated in their meta-analysis 
that anodal RV shocks for the first phase of a biphasic shock are superior45. 
The trend currently seems to be to reduce the need for defibrillation testing at 
implantation and therefore requiring that the optimal defibrillation waveform be 
empirically programmed at the outset46;47. 
The biphasic waveform typically consists of two monophasic pulses with leading 
edges greater than the trailing edge. The level of voltage decay between the 
leading and trailing edges may be set typically as 50%, at which point a polarity 
inversion occurs and a further 50% decay of voltage occurs to termination 
(Figure 1.3.2). 
There are fixed tilt and phase duration systems such as the Medtronic ICD 
population (Medtronic Inc. MN. USA). This is typically set at 2.6 ms/2.8 ms (first 
and second phases, respectively). The optimal formation of this biphasic 
waveform has been contentious. Commercially available ICDs typically discharge 
a defibrillation waveform having a 50%/50% or 65%/65% tilt to each phase.  
Evidence also suggests that pulse width programming or a “tuned” phase 
duration programming is more effective than fixed tilt programming28;48. Arguably, 
new generation devices may require more flexible defibrillation waveform 
programming to deal with high DFT situations.  
This may be explained by understanding the relationship of membrane charge 












The value of Tau may be influenced by myocardial fibre orientation and 
composition, which takes into account the scar content of the myocardium. It 
therefore seems that a fixed tilt waveform may be suboptimal.  
This would suggest that the optimal biphasic waveform requires match between 
the time constant Tau of the defibrillation system and the cell membrane. The 
diagrammatic representation of a biphasic shock waveform against membrane 
response in Figure 1.3.3 shows that the first phase reduces the peak membrane 
response, and then the second phase returns the membrane potential to zero40. 
However, phase two persists beyond the zero point for a few milliseconds, which 





















Diagrams of the monophasic components of defibrillation waveforms. 
(Reproduced from From Cell to Bedside 5th ed. Zipes 200910). 
Truncated exponential ascending 
waveform 
Truncated exponential descending 
waveform 
Damped sine wave 




























Figure 1.3.2  
A biphasic truncated exponential descending waveform with 50% tilt of both 
phases. Polarity reversal occurs after the voltage has decayed to 50% from the 
leading edge in phase 1 then a decay of 50% from the leading edge in an 
inverted phase 2. Thereafter, the waveform is truncated.  
The phase durations (X and Y) are programmable in some devices; 






























Figure 1.3.3  
A theoretical biphasic waveform with equal tilt with a matched membrane 
response. 
(Reproduced from From Cell to Bedside 5th ed. Zipes 200910). 


















Upper Limit of Vulnerability 
Sub-threshold shocks delivered within a vulnerable zone of repolarisation (during 
the T wave) may induce VF. However, with incremental shock energies VF 
becomes no longer inducible. This critical point is termed the upper limit of 
vulnerability (ULV), which interestingly corresponds to the DFT40;49;50. 
Cellular Manifestations of Shock Delivery 
Optical mapping studies in cellular mono-layers indicate that changes in trans-
membrane charge induced by shocks are non-linear. This is asymmetric and 
characterised by a greater negative polarity, presumably due to calcium leaking 
through the positive areas of the cell membrane. This links the concept of 
electroporation with the shift in cell membrane potential, in response to a strong 
shock51;52. 
Mechanisms of Initiation 
Ventricular arrhythmias are initiated either by: 
1. Macrore-entry 
2. Early after depolarisations (occurring in phase 1 and 2 of the action potential) 
as in the case of Torsade de Pointes and Long QT syndromes. 
3. Delayed after depolarisations (phase 4) 
4. Abnormal automaticity 













In the case of acute ischaemia, the KATP channel is opened causing acidosis and 
anoxia in cardiac muscle. The result of K+ efflux is a large dispersion of 
repolarisation across the border-zone of the ischaemic region. Tissue excitability 
increases resulting in spontaneous activations.  
For re-entry to occur, two criteria must be met: 
1. There must be a unidirectional block within the myocardial substrate  
2. The cycle length of the tachycardia must exceed the longest refractory 
period of the myocardium. 
The action potential duration (APD) in ventricular myocardium is heterogeneous. 
The duration is longer at the base of the heart than at the apex and longer in the 
endocardium than in the epicardium, but longest at the mid-myocardial layer (M-
cell layer). This dispersion in APD may be the cause of VF generation in 
diseases such as Brugada Syndrome and the Long QT syndrome53;54. 
Ischaemic Ventricular Fibrillation 
The border-zone areas of regional ischaemia leading to electrical heterogeneity 
have been identified as the substrate and site for the generation of triggers 
initiating VF55. Thrombotic occlusion of coronary arteries is more likely to be 
associated with VF than non-thrombotic occlusions. The rise in extracellular K+ 
and Na+ (due to Ca2+-Na+ exchange) contribute to the excitability of tissue. 
Norepinephrine levels become elevated within border-zones following ischaemia. 
These factors create a critical milieu that provides the catalyst for electrical 












Effects of Repeated Defibrillation on Myocardium 
The effects of direct current, electrical shock on myocardium have been studied 
in animals and there is anecdotal evidence from post-mortem human specimens. 
Focal areas of coagulation necrosis with haemorrhage occur in the 
subepicardium. At an ultra-structural level, there is disruption of the intercalated 
discs56. Modest elevations of the cardiac enzymes have been noted to occur57. 
The electrical shock also may alter the appearance of the ST segment and T 












1.4 Ventricular Fibrillation Induction 
Ventricular fibrillation is typically induced in a clinical setting using the following 
techniques: 
1. Pacing using high frequency alternating current delivered from the ICD to 
the myocardium either through endocardial or epicardial electrodes at 60, 
50, or 30 Hz as described by Kleiman et al.58. 
2. Delivery of a low energy shock (typically 1J) during the vulnerable part of 
the T wave after a short ventricular pacing train. 
3. Application of direct current though the pace/sense electrodes. This is 
referred to as DC Fibber in ICDs manufactured by St. Jude Medical (St 
Paul’s, MN, USA). 
4. Delivery of sub-threshold shocks until the ULV threshold is reached59. 
The relevant induction protocol to each experiment has been elaborated on in the 












1.5 Clinical Trials and the Impact on ICD Development 
The ability of the ICD to save lives in survivors of cardiac arrest has been 
demonstrated in these landmark secondary prevention trials: Arrhythmia Versus 
Implantable Defibrillator (AVID) trial, Canadian Implantable Defibrillator Study 
(CIDS) and Cardiac Arrest Study Hamburg (CASH)40;60-62 Factors that influenced 
the benefit of ICDs included an ejection fraction <35%, increased age, and heart 
failure. 
The primary prevention trials include MADIT, MUSTT, MADIT II, which went on to 
demonstrate the benefit of ICDs implanted in patients with ischaemic 
cardiomyopathies as a primary prevention strategy49;63. 
 The CABG-Patch trial, however, showed no benefit  with prophylactic ICD 
implantation in patients receiving coronary artery bypass40;64. 
 The DEFINITE and SCD HeFT extended the indication to include patients with 
non-ischaemic cardiomyopathies64. 
 The indications for defibrillators are therefore expanding. This places a need for 
evolving technology including extended battery longevity, improved detection 












1.6 Painless Anti-Tachycardia Therapy 
Anti-tachycardia pacing has been shown to reduce pain and psychological 
trauma following defibrillation49;65. There is increasing data to suggest that shock 
delivery, whether appropriate or inappropriate, also portends a poor prognosis, 
predicting increased mortality from progressive LV dysfunction and heart 
failure66. 
The PAINFREE II Rx trial helped advance the idea of empiric ATP for an episode 
of VT, even though it is identified in the VF zone. The ATP will be discharged first 
as long as the rhythm remains stable67. This option is programmable and helps 
reduce the number of shock therapies, reducing morbidity, and conserving the 
ICD battery. 
The ATP is programmable for the number of pulses and coupling intervals. A 
fixed set of equally spaced pulses is referred to as a “burst”. A “scan” refers to a 
decrement in the interval between successive burst sequences if the criteria for 
rhythm termination after ATP are not identified. The ATP may then be 
programmed to become more aggressive so that there is always an escalation of 
therapy in the case of an ongoing event and never a step down in therapies. 
This may consist of a “ramp” where there is a decrement between each delivered 
pulse. Each pulse may also be programmed at individual coupling intervals and 












At the same time, ATP can be deleterious.  Overzealous ATP programming can 
result in eventual progression of shock delivery, which may result in a prolonged 
period of VT or VF.  
Anti-tachycardia pacing can potentially be pro-arrhythmic if delivered 
inappropriately. On the other hand, ATP can be used as a diagnostic tool 
depending on the interaction it yields with the underlying tachycardia.  
I explore the incidence of ITS from ICDs in a clinical context and explore the 
diagnostic applications of failed ATP and its potential for active/dynamic 












2. Overview of Experimental Design and Methods for Animal Studies 
2.1 Animal Selection and Characteristics Relevant to Ventricular 
Arrhythmia Induction and Defibrillation 
Both canine and porcine models have been used in large animal defibrillation 
studies because of the ability to procure the animals as well as their comparable 
cardiac anatomy to humans68;69. The porcine heart bears closer resemblance to 
human cardiac structure. In contrast, the canine heart has greater myocardial 
bulk, presumably because of higher levels of activity70. 
Landrace pigs were chosen for these experiments, as they are commercially 
bred and easier to obtain than dogs for scientific procedures.  
The following non-clinical experiments used pigs as test subjects: 
 Assessment of a sequential defibrillation waveform in a prototype serial 
capacitance defibrillator (Chapter 4). 
 An investigation of multi-site right ventricular endocardial electrode 
placement on measures of defibrillation outcome (Chapter 5). 
 Transthoracic defibrillation studies (Chapter 6). 













Electrophysiological Comparisons between the Pig Model and Humans 
The measured R wave from the pig`s electrocardiogram is in the order of 5.9–
10.4 mV and for man this has a comparable range of 6.9–17.9 mV, whereas the 
R wave in the dog ranges between 24.0–30.0 mV reflecting its thicker 
myocardium. The QT interval in the pig is longer, hence the relative ease in 
inducing VF with T wave synchronous sub-threshold shocks71. 
The mean VF cycle length in humans is 200 ms compared to 95 ms in pigs. 
Martin and colleagues compared the temporal characteristics of VF among seven 
patients with previously analysed swine data72. 
In the patients, VF frequency was 4.23 ± 0.93 Hz at onset, which then ebbed 
displaying bimodal peaks at 4.4 ± 1.01 Hz at 55 sec and 3.98 ± 0.5Hz at 5.47 ± 
0.45 min (Figure 2.1.1 A).  
In the pigs, the initial VF frequency was 13.5 ± 1.68 Hz at induction, which ebbed 
to 8.6 ± 0.87 Hz at 1.22 ± 0.19 min. This was followed by a single peak of 13.7 ± 



















 Plot of the median frequency of VF in seven human subjects. The 
frequency is shown over time in minutes and the standard deviation is 
indicated by dotted lines. 
(Reproduced from Frequency analysis of the human and swine 


















Plot of the median frequency of VF in eleven pigs. 
The frequency is shown over time in minutes with the standard deviation 
depicted by dotted lines. 
(Reproduced from Frequency analysis of the human and swine 














2.2 Animal Preparation and Handling 
Experiments were batched, with only one experiment per day and two to three 
per week. This was done to optimise the use of laboratory resources as well to 
allow sufficient time for the animals to acclimatise to their new surroundings. The 
pigs were also brought in five days prior to the scheduled experiments in order to 
reduce the stress levels of the animals prior to experiments. An additional 
challenge was to control the feeding and weight of the pigs prior to experiments 
to maintain uniformity between the study subjects since weight influenced 
defibrillation thresholds. 
Premedication 
On the day of each experiment, animals were sedated with an intramuscular 
injection of Azperone (Stresnil) at 2 mg/kg approximately 30 min prior to 
anaesthesia. 
An intravenous cannula was inserted into an ear pinna vein. A bolus dose 
Alfaxalone/Alfadolone acetate (Saffan) was administered intravenously for rapid 
induction. The animal was then immediately transported to the operating table. 
Intubation Technique 
The epiglottis of the pig is longer than in humans and tends to obstruct vision of 
the cords and larynx. This was obviated by placing the pig in the left lateral 
position. A laryngoscope with an elongated straight blade was used to depress 












expose the cords and larynx. The larynx and vocal cords were then sprayed with 
Xylocaine.  
A cuffed endotracheal tube was then advanced over a trocar into the trachea and 
the cuff was inflated. The animal was ventilated with a mixture of Oxygen (100%) 
and Isofluorane (5% initially, then reduced to 2%) with flow rates of 2–3 L/min. 
The tidal volume was calculated at 10 mL/kg. A CapeWain Multipurpose 
ventilator (Cape, Warwickshire, UK) with a soda lime carbon dioxide extraction 
system was used. Additional Saffan boluses were administered intravenously if 
required to deepen anaesthesia. 
Monitoring 
All animals were monitored using cutaneous surface ECG recordings with a 
Hewlett Packard HP 78353B (Hewlett Packard, CA, USA) monitor.  
Intracardiac electrogram recordings were monitored through the pace/sense 
component of a defibrillator lead after positioning within the RV using the 
respective ICD programmer (Symphony, Ela Medical, Sorin Group, France or 
Medtronic analyzer).  
A cut down to a femoral artery was performed and an indwelling cannula was left 
in situ to maintain continuous intra-arterial blood pressure recordings. Femoral 
vein access was also established for administration of fluids (0.9% saline). 













All experiments were non-recovery. At the conclusion of each experiment 
animals were administered a lethal dose of sodium pentobarbital at 20 mg/kg. On 
cessation of cardiac activity, the ventilator was turned off. The animal was 
observed for absence of respiratory effort and cardiac function. The animals were 
disposed of by incineration. In some cases, an autopsy of the heart was 
performed before disposal to assess for macroscopic evidence of cardiac trauma 
from repeated defibrillation and to assess the position of the electrodes, 












2.3 Anaesthesia Choice and Anticipated Interactions 
The intravenous preparation of Saffan is a mixture of 9 mg Alfaxalone and 3 mg 
Alfadolone acetate and was administered at 0.5–1.0 mL/kg/h. The effects of 
Saffan on the cardiovascular system were studied by Cox et al., who noted a 
progressive increase in heart rate with its use73. This was postulated to be due to 
a vagolytic mechanism at a suprapontine level. 
Isofluorane was used as the inhalation agent for maintenance of anaesthesia and 












3. Ethical Considerations and Safety Measures for Animal Usage. 
All animal studies were carried out in a secure and managed biomedical facility 
attached to the Southampton Universities Hospital Medical School, UK.  
The pigs used in these experiments were obtained from an approved and 
registered supplier to the University of Southampton.  
Both the supplier and biomedical facility held a certificate of designation under 
the Animals Scientific Procedures Act of 1986 to perform regulated procedures 
on non-protected animals. Scheduled and unscheduled inspections were 
conducted by a delegate from the Home Office to ensure compliance with ethical 
standards for animal care. All animal technicians and handlers were employed by 
the University and held personal licenses regulating their level of involvement 
with animal experimentation after undertaking appropriate training and 
examinations conducted by the Home Office. All project and personal licenses 
required annual review and renewal. 
The working conditions of all animal handlers, including surgeons were regulated 
under the Health and Safety Act in the UK. All animal handlers and surgeons 
wore surgical scrubs, protective overshoes, and gloves. The surgeon was 
required to wear a surgical cap, mask, and gloves during the procedures. Lead 
aprons were worn by all personnel present within the operating room whenever 












All lead aprons were routinely checked by Southampton General Hospital’s 
radiology services for compliance and all primary operators wore TLD dosimeters 
on their torso, headgear, and a ring TLD for hand exposure monitoring. 
A project licence (PPL: 30/2044) was granted to Dr John Morgan and Dr Paul 
Roberts, my senior supervisors in the UK, to conduct the animal experiments 
contained in this work. 
I was granted a personal License by the Institute of Biology after attending an 
approved training course in order to undertake the specific procedures conducted 
on animals as detailed in this thesis.  
The animal usage and number per study was chosen with adherence to concepts 












4. Assessing A Sequential Optimised Defibrillation Waveform in a 
Prototype Serial Capacitance Defibrillator. 
4.1 Does a Monophasic Preshock Improve the Defibrillation Efficacy of a 
Conventional Biphasic Waveform? 
Introduction 
In a previous study, Roberts et al. demonstrated that a nominal preshock 
delivered from a lead placed in the middle cardiac vein in a porcine model 
succeeded in reducing defibrillation energy requirements in all configurations 
incorporating the preshock30. This, however, was not evaluated as a sequential 
discharge from within the RV, which is the conventional transvenous lead 
location. Post-mortem analysis of the pigs used in that study showed evidence of 
contusions around the middle cardiac vein, even from these nominal preshocks, 
making the endocardial preshock delivery more desirable. Furthermore, in his 
thesis, Dr Paul Roberts (“An Examination of Pathways of Defibrillation”, 
University of Leeds, School of Medicine, February, 2000) speculated about 
delivery of the preshock and a definitive shock from a single capacitor in order to 
minimise delay between the waveforms. This chapter expands on this work with 
the use of a prototype device. 
In this study, a prototype defibrillator using two Alto2 defibrillator capacitors was 
constructed in close collaboration with the Ela Medical (Sorin Group, France) 
research and development team. Although consisting of two capacitors, as in 












function as a single capacitance unit. A custom software patch named elaterm 
was designed and uploaded to a laptop computer to program and configure 
waveforms and to activate the device via a header adapter used to establish 
telemetry between the computer and the non-implantable device.  
The external prototype device was connected to an emulator Can and to a 
standard defibrillator lead which was implanted in the pig (detailed in the 
methods section below).  
Objectives: 
1. To assess the influence of a preshock delivered before a biphasic 
definitive shock, in a conventional RV endocardial configuration on DFTs. 
2. To assess the functionality of a prototype serial capacitance device and its 













Animal Selection and Preparation 
Six female Landrace pigs of 30–40 kg with normal hearts were anaesthetized 
using isofluorane and monitored using the method previously described. All 
experiments were non-recovery with euthanasia of the animals as previously 
described (Section 2.3). 
A cut down to the left internal jugular vein was performed and a dual coil 
defibrillator lead (Medtronic 6931, MN, USA: 2.3 mm 7F, 62 mm RV electrode 
coil length, surface area = 513 cm2) was inserted under fluoroscopic guidance 
into the right ventricular apex (RVA) (Figure 4.1.1 and Figure 4.1.2). The SVC 
electrode was excluded from the circuit.  
The defibrillator lead used in this experiment was chosen prior to knowledge of 
the high incidence of 7F lead related failures74. 
The pace/sense component of the implanted defibrillator lead was inserted to the 
corresponding IS-1 port of an Alto VR 625 single chamber ICD (Ela Medical 
Sorin Group, France) and was not implanted into the animal. This device was 
used to conduct sensing and pacing threshold tests and to induce VF with 30Hz 


















                       
 
Figure 4.1.1  
The dual coil 7F Medtronic 6931 






















A. With the pig in a left lateral position, the site of dissection to the left 
internal jugular vein is shown with the emulator Can implanted into the left 
pre-pectoral site. 
B. luoroscopic position of the distal RV coil electrode at the apex of the 
right ventricle is shown in a left lateral view. 
 






The dissection site and th  defibrillator lead position.  
A. With the pig in a left lateral position, the si e of dissection to the left 
internal jugular vein is shown with the emulator Can implanted into a left  
pre-pectoral pocket. 
B. The fluoroscopic pos tion o  the distal RV coil electrode at the apex of the 
right ventricle is shown in a left lateral view. 
A 
B 
Cut down to right internal 
jugular vein 
Standard MSP 625 Alto2 
ICD used for VF induction 
and intra-cardiac signal 













R wave sensing of ≥ 5.0 mV with a pacing threshold of ≤ 2.0 V at 0.5 ms was 
regarded as acceptable for a stable lead placement. 
The RV high voltage component of the lead was attached to the external 
prototype defibrillator by crocodile clips to the DF-1 component of the lead. It 
could be programmed cathodal/anodal through the prototype ICD. 
An emulator active housing based on the 9001 Defender ICD (surface area = 75 
cm2, 84.9 mm x 60 mm x 19 mm, Ela Medical Sorin Group, France) was 
implanted into the left pre-pectoral region to resemble clinical implantation and 
was then sutured into the pocket. This, in turn, was also connected by crocodile 
clips to the prototype ICD and therefore could have the designated polarity 
adjusted to +/- in the same way.  
Defibrillation Protocol 
Ventricular fibrillation induction was performed using three modalities in a 
sequential fashion if the preceding step failed to induce true VF. 
30Hz Burst pacing from this externally connected ICD was delivered through the 
endocardial lead for 5 seconds duration. If this failed to induce VF, a T-wave 
shock was employed.  
Custom software called elaterm (Ela Medical, Sorin Group, France) was 
uploaded to a dedicated laptop. The energy for defibrillation was programmed 
into the external prototype defibrillator using telemetry via a wand adapter 












Defibrillation testing was conducted using a binary up/down method with a 3-
stage reversal pattern (Figure 4.1.3).  Shock energies were programmed 
commencing at 13.9 J and delivered by the device in either a biphasic format 
alone (control) or with a preceding pre-shock (test) followed by a biphasic shock. 
The control or test shock DFT protocol was randomised. If this initial energy 
shock failed to defibrillate, the energy was increased in the next stage of the 
binary method to 19.8 J and the induction was repeated. If the 19.8J shock was 
ineffective, then the next step up would have been to 26.8 J and then to 28.7 J. 
This describes the sequential step up process. 
 If the 13.9 J shock was effective, the next induction and defibrillation was 
stepped down to 9.0 J. 
Depending on the success or failure of this defibrillation, a step up or step down 
of energy was programmed.  
The final energy for which defibrillation was successful was regarded as the DFT. 
The protocol was repeated and the average of the two DFTs was then taken as 
the final DFT for the protocol (control/test). 
After each induction and shock delivery, a three minute recovery was observed 






















































6.96 11.3 16.7 26.8 
6.03 7.9 9.0 13.9 15.3 19.8 23.1 28.7 
Figure 4.1.3  
The binary up/down 3- reversal defibrillation protocol. 
 This schematic illustrates the protocol used to perform the defibrillation threshold test. 












Description of the Control and Test Shock Waveforms 
A standard biphasic shock was delivered with an initial phase polarity of Can > 
RV coil (SVC coil was excluded) and a 50% tilt and 2.8 ms duration to both 
phases was regarded as the control waveform. 
The preshock was a monophasic waveform with a RV (anode) > Can (cathode) 
orientation, tilt was automatically adjusted (non-programmable) in order to deliver 
a third of the total programmed capacitor discharge with a fixed 1ms phase 
duration.  
The total energy dissipation in between preshock and the biphasic waveform was 
in a 1:2 ratio and is illustrated in Table 4.1.1. 
Rescue Shock Delivery 
Rescue shocks, in cases of a failed defibrillation, were delivered initially at a 
maximal discharge (30.1J) from the prototype device as a standard biphasic 
waveform with 50% tilt for both phases with a Can > RV coil initial polarity. If this 
failed, a transthoracic 200J external biphasic shock was used. 
The concern after delivery of high-energy rescue shocks was the degree of 
electroporation cellular injury and the impact on subsequent DFTs. Thus, rescue 
shocks were first delivered endocardially before a transthoracic delivery and in a 
biphasic format so that the second phase was reparative from the initial electrical 























   
6.0 2.0 4.0 
7.0 2.3 4.6 
7.9 2.6 5.3 
9.0 3.0 6.0 
11.3 3.8 7.5 
13.9 4.6 9.3 
15.3 5.1 10.2 
16.7 5.6 11.1 
19.8 6.6 13.2 
23.1 7.7 15.4 
26.8 8.9 17.9 
28.7 9.6 19.1 





Table 4.1.1  
Stored energy (Joules) dissipated in a 1:2 ratio between preshock and 












Defibrillation Waveform Characteristics 
The shock waveform consisted of an initial monophasic initial preshock followed 
by a randomised, adjustable inter-shock interval (ISI) preceding a conventional 
tilt dependent biphasic discharge (Figure 4.1.4). 
Preshock: This was a monophasic discharge from the capacitor with the distal 
RV electrode denoted cathodal (-). The emulator Can and SVC coil (included in 
the circuit) were both anodal (+). The energy dissipated by the preshock was 
fixed as a third of the total discharge (including the definitive biphasic phase). 
This then determined the tilt of this auxiliary waveform as the phase duration 
remained 1 ms. 
Definitive shock: Biphasic waveform delivered with the distal electrode (RV) 
being anodal for the first phase with 50% tilt from the lead edge and 15 ms phase 
duration. Thereafter, a reversal of polarity for the second phase was programmed 
with 50% decay from the leading edge as well.  
Inter-Shock Intervals (ISIs): The inter-shock interval was defined as the interval 
between the monophasic discharge and the biphasic phase. These were 
programmable through a custom designed software patch (elaterm, Ela Medical, 
Sorin Group, France) that allowed interval increments up to 100 ms. 
However, the ISIs chosen were limited to three, as having more permutations 


















Figure 4.1.4  
           
Control and test waveforms 
 A. The control shock waveform consisting of a single biphasic 
shock delivered at Can > RV, for the initial phase polarity. 
 B. The test waveform consisting of a preshock preceding the 
definitive biphasic shock.  
Preshock 
Can→RV 
Biphasic shock 50% 










50% tilt for both phases each 














This may not have been tolerated by the animal. Furthermore, the data derived 
later in the protocol would be made less reliable. The ISIs included 16, 31, and 
47 ms (Table 4.1.2). 
 These were arbitrarily chosen but the selection was guided by the maximum 
duration of the ISW as measured by optical mapping means using voltage 
sensitive dye from previously established data76. 
The order of testing between control and each test interval was randomised. 
The Prototype Serial Capacitor 
The custom manufactured defibrillator was based on a commercially available 
ICD, the Alto 2 MSP 625 (Ela Medical, Sorin Group, France). 
The prototype device was effectively a single capacitive defibrillator consisting of 
two serially arranged capacitors derived from the above mentioned ICD providing 
a combined capacitance of 105 µF. 
Shocks are delivered by an H-Bridge composed of 4 switches (SW1–4) (Figure 
4.1.5). These are activated sequentially and in pairs, in order to deliver a 
preshock. This also allowed the preshock to be delivered either as a monophasic 
or biphasic waveform if required. 
The second definitive shock could likewise have been manipulated into a 
monophasic or biphasic basic format. The chosen waveform for the second 



























Permutation1  Can(+)→RVA(-) 0ms (control) 
Permutation2 Can(+)→RVA(-) Can(+)→RVA(-) 16ms 
Permutation3 Can(+)→RVA(-) Can(+)→RVA(-) 31ms 
Permutation4 Can(+)→RVA(-) Can(+)→RVA(-) 47ms 
 
 
Table 4.1.2  
Permutations of defibrillation testing.  
Defibrillation testing was randomised between each of the above 












The shock phases are either limited by the tilt with the amplitude of the leading 
edge determined by voltage in units of 25 V or by duration that was 
programmable in milliseconds. The ISIs were programmable to the following 
intervals only: 16, 32, and 47 ms. Both the non-implantable prototype ICD and 
the elaterm software patch to program its functions were constructed by the 
Research and Development team from Ela Medical, Sorin Group, France 




All data were captured into an Excel spreadsheet and are represented as the 
mean ± standard deviation. Where relevant, statistical tests of significance were 
performed using a paired t-test.  
Correlations were undertaken with a Spearman factor correlation for non-






























Figure 4.1.5  
Diagrammatic structure of the prototype defibrillator.  
This consists of serially arranged capacitors linked to an “H-Bridge” 
design comprised of four switches (SW). A shock entailed activation of 
SW1 & 4 for the first phase and then SW 2 & 3 for phase 2.  
Delivery of a preshock required activation of a pair of switches before 













This study was conducted in 6 anaesthetised, close chested female pigs 
weighing 38.7 ± 7 kg.  
There was no significant DFT reduction between a control of a standard biphasic 
shock and the test waveform of a nominal preshock (p > 0.05) for all 
permutations. The preshock alone never terminated VF.  
Equivalent DFTs to the control were observed with the shortest ISI of 16 ms in 
the test waveform protocol (p = 0.9). Larger ISIs between a monophasic 
discharge and the biphasic definitive shock resulted in higher DFTs, but again 
these were not statistically significant (31 ms; p = 0.1 and 47 ms; p = 0.2) 
(Figures 4.1.6 and 4.1.7). 
There was a linear correlation of the mean DFTs in each tested permutation 




























Figure 4.1.6  
Linear graph depicting DFTs vs. ISIs. 












































































Averages control 16ms 31ms 47ms
DFT (joules) 17.8±5 18±3 22±5 23±5
Impedance (ohms) 48.7± 6 47.4±4 48.2±5 49.2±5





Figure 4.1.7  


















Figure 4.1.8  













Previous studies have demonstrated the efficacy of sub-threshold shocks in 
generating an electrically quiescent period referred to as an ISW77 The exact 
mechanism of the ISW is not fully understood. This may represent undetected re-
entry or a graded propagated response post defibrillation. This ISW is a variable 
period and its duration is dependent on the energy delivered78-80. 
The effect of successful and failed defibrillation was studied in isolated normal 
pig hearts using voltage sensitive dye and dual-camera video imaging by 
Chattipakorn et al.76. Fluorescent signals were derived from the anterior and 
posterior myocardial walls. A post-shock interval period with no recordable 
electrical potential differences was noted and termed the iso-electric window. 
The activation of the first post-shock cycle after a failed attempt started 78 ± 32 
ms after the shock as determined by optical mapping studies76.  
We postulated that a biphasic shock delivered within this ISW would prevent re-
initiation of VF, effecting return to normal sinus rhythm with an overall lower DFT. 
The preshock that was delivered in the test waveform in this study would have 
been responsible for brief ISW prior to delivery of the primary biphasic shock. 
Although the ISW was not measured in this study, the ISIs investigated (16, 31, 
and 47 ms) were arbitrarily assigned but remained within the minimum measured 
ISWs determined from prior data80. 
Improved defibrillation efficacy facilitated by delivery of a multiphasic waveform, 












Supposedly, the preshock then induces a homogenous myocardial cellular 
charge thus reducing overall defibrillation energy requirements for complete 
defibrillation by the definitive biphasic waveform. 
The alternate hypothesis relates to the upper limit of vulnerability theory 
postulated by Chen et al.11. This suggests that failed defibrillation energy actually 
serves to reinitiate VF after negating myocardial fibrillation.  
By deduction therefore, sub-threshold shocks are in essence successful in 
terminating VF, but also have the potential to be pro-arrhythmic. These sub-
threshold shocks showed re-initiation of VF after a shorter ISW in the above 
study. 
In this study, the definitive shock was delivered at a critical period after a sub-
threshold monophasic discharge. The net effect presumably would have been a 
reduction in DFTs. Results of this experiment however, show equivalence to the 
control of a standard biphasic shock and even a trend to DFT increase with 
increasing ISIs beyond the nominal 16 ms. 
Despite these factors, the prototype serial capacitor concept proved feasible, 
allowing software manipulation of the waveform with relative ease. This software 
patch (elatermP) was based on a commercially available system in the Alto2 
platform (Ela Medical, Sorin Group, France). It is therefore conceivable that 
additional programmability with multi-sequence defibrillation waveforms for future 












Previous studies have demonstrated the advantage of a “tuned waveform” with a 
“matched time membrane constant” of myocardial cellular membrane to the 
defibrillation system thus optimising defibrillation83.  
Standard ICD technology offers waveform programmability to invert polarity of 
the biphasic truncated exponential decay pattern as well as to alter the pulse 
wave duration in certain devices. These measures show an advantage in that 
they may improve DFTs where thresholds are high and no safety margin can be 
maintained with standard configurations. The secondary advantage is an 
optimally delivered waveform with matched system and membrane time 
constants, minimizing local cellular injury and possibly reducing the risk of 
progression to heart failure post shock delivery84. 
Limitations 
A limitation of this study is that the ISI was not actually measured but assumed 
based on prior studies and therefore the ISIs were arbitrarily chosen for these 
test permutations. The preshock was standardised but was varied in a 1:2 ratio 
with the second biphasic capacitor discharge. This, therefore, would have more 
likely resulted in variability of the ISW for each ISI that was tested. 
There is also evidence that triphasic and additional waveforms improve 
DFTs85;86. It is therefore arguable whether the monophasic preshock merely 














This study validated the use of a serial, single capacitance prototype defibrillator 
in producing a preshock followed by a definitive biphasic waveform delivered in 
sequence. The mean defibrillation energy, however, was equivalent between this 
test waveform and a control consisting of a standard biphasic waveform. The use 
of larger ISIs between the monophasic preshock and definitive biphasic shock 
showed a trend to increased DFTs. 
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4.2 An Assessment of the Influence of Polarity of a Monophasic Preshock 
on Defibrillation Efficacy. 
Introduction 
Recent data has shown evidence that delivery of a biphasic shock with the RV 
electrode designated anodal, results in enhanced defibrillation efficacy45. This 
has resulted in a change from the convention of programming the distal RV 
electrode as cathodal to anodal for a biphasic shock waveform. 
In this pilot experiment, I evaluated the optimal polarity of a monophasic 
preshock in relation to a standard definitive biphasic waveform. In addition, the 
programmability and efficiency of a prototype serial capacitance device was 













Animal Selection and Preparation 
Five female Landrace pigs weighing 48.4 ± 9.1 kg were anaesthetised and 
prepared in the manner previously described in Section 2. 
A cut down to the left internal jugular vein was performed and a defibrillation 
electrode (Medtronic 6931, MN, USA: 2.3 mm 7F, 62 mm RV electrode coil 
length, surface area = 513 cm2) was placed under fluoroscopic guidance in the 
right ventricular apex and an emulator Can was implanted as described in the 
preceding chapter .  
Defibrillation Protocol 
The ventricular fibrillation induction and defibrillation binary up/down protocol was 
maintained as in the preceding experiment in Chapter 4.1 (page 51) for 
uniformity. The defibrillation protocol entailed configuration 1, which was 
delivery of a monophasic preshock with an active anodal Can electrode for the 
preshock and 1st phase of the biphasic shock) separated by a 16 ms ISI (defined 
as optimal  for this device in Chapter 4.1). Thereafter, the polarity was reversed 
to the RV coil as the anode for the 1st phase as well as for the preshock (Table 
4.2.1). This waveform inversion was applied for the defined ISI. Testing was 













Only the RV coil and active Can electrodes were included in the circuit (the SVC 
coil was excluded) by connecting each externally to the anodal and cathodal 
poles, respectively, of the prototype defibrillator referred to in 4.1 (Ela Medical, 
Sorin Group, France).  
A custom software patch entitled elatermP allowed a sequential dissipation of a 
selected energy into a preshock and definitive biphasic shock in a 1:2 ratio from 
the serially arranged capacitors (Figure 4.2.1) as was described previously. 
Statistical Analysis 
The mean DFT, shock impedance, and VF duration was calculated and 
represented as mean ± standard deviation. A 2-tailed paired t-test was used to 
determine statistical significance between configurations (normal vs. inverted 





























C(+)→R(-) C(+)→R(-) R(+)→C(-) C(+)→R(-) 16ms 
 
 
Table 4.2.1  
Polarity configurations and the ISIs achieved through the prototype device. 
(C= active Can electrode, R = right ventricular coil electrode).  
 



















Figure 4.2.1  
Control and configuration 2 waveforms: 
A. The control shock waveform consisting of a single biphasic 
shock delivered at normal polarity with phase reversal after 50% 
decay from the leading edge. 
 B. The configuration 2 waveform consisting of a pre-shock 
(reversed polarity) preceding the definitive biphasic shock in a 1:2 
energy dissipation of the stored energy. 
preshock 
Can→RV 
shock 50% tilt both 











50% tilt for both phases each 15ms 
















The distribution of DFTs and median values are shown in Figure 4.2.2. 
There was no significant difference in the mean DFT values (p = 0.1) between 
configuration1 (DFT1) and configuration 2 (DFT2).  
There was also no difference between the mean shock impedances and VF 
durations between each configuration (p = 0.3 and p = 0.1, respectively).  























Figure 4.2.2  
A plot of the range (50%) of DFTs in configurations 1 (DFT1) and 2 
(DFT2). The dark line represents the median while the whiskers show 
the highest and lowest recorded values. 
Range (16.7-30.6)J; 
Median = 19.8J 
Range (13.9-26.8)J; 


































Table 4.2.2  
Summary of defibrillation results by group and weight. 
 













In the preceding chapter, I demonstrated the feasibility of producing a monophasic 
preshock followed by a biphasic waveform. This sequential waveform was produced 
by a prototype serial capacitance defibrillator. The outcome, however, was equivalent 
to that of a standard 50% tilt biphasic waveform. An optimal ISI of 16 ms was 
established from this preliminary work. 
Recent evidence suggests that delivery of the first phase of the shock waveform 
should have the RV electrode assigned as anodal resulting in an implosion of colliding 
wavefronts at the RV electrode rather than an expansion which may be pro-
arrhythmic87. 
In this study, I investigated the ability to deliver a monophasic preshock through a 
prototype serial capacitance device with alternate polarity settings and the effect of 
this polarity setting on defibrillation efficacy. In this pilot study, no statistical difference 
was demonstrable between preshock deliveries with a distal cathodal RV electrode vs. 
anodal polarity.  
The exception being that of experiment 5 which revealed a 5.9J reduction in DFT with 
configuration 2 but this may also have been influenced by a reduced VF duration and 
shock impedance rather than purely the result of a polarity change. The overall effect 













The theoretical benefits of an RV anode are related to the virtual electrode effect of 
inducing a positive charge on neighbouring myocytes. This then results in imploding 
wavefronts rather than expanding electrical energy during the delivery of a shock45. 
Despite this benefit, this polarity may potentially cause greater acute cellular 
membrane injury. This effect is called electroporation and has been previously defined 
in this work. It is however a transient phenomenon as the second phase of a biphasic 
shock results in “repair” of the cellular damage. However, an anodal monophasic 
preshock may be responsible for greater cellular membrane injury.  
Limitations 
The obvious limitation in this experiment is the small sample size. However, this was a 
pilot experiment to determine whether the polarity of the preshock has any obvious 
influence on DFT. The random nature of the DFTs obtained in these five experiments 














Delivery of a monophasic preshock, delivered with distal anodal polarity as opposed to 
a RV cathodal electrode, did not consistently improve defibrillation efficacy. Preshock 
polarity reversal offers no further benefit to defibrillation outcome. 
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5. An Investigation of Multi-Site Right Ventricular Endocardial Electrode 
Placement on Measures of Defibrillation Outcome. 
Introduction 
In a clinical setting, elevated defibrillation thresholds may be influenced by factors in 
the substrate or in the defibrillator system. These may be improved by repositioning 
leads, upgrading to higher energy devices, or altering the shock waveform or 
defibrillation vector. The use of additional defibrillator electrodes implanted at 
extracardiac locations, e.g. subclavian vein, SVC, pulmonary artery, coronary venous 
system, have also been shown to enhance defibrillation, presumably by increasing the 
electrode surface area exposed to defibrillation as is explained by the critical mass 
hypothesis10. 
My colleague, Dr John Paisey, examined the use of defibrillation incorporating 
electrodes in the pulmonary artery and middle cardiac vein (unpublished data from his 
thesis entitled “Defibrillation, the Coronary Venous System and the Passive Electrode 
Affect”, Southampton University School of Medicine, July 2004). It has not been 
shown whether just increasing the number of endocardial electrodes at a conventional 













Eight female Landrace pigs weighing 21.4 ± 1.2 kg were prepared in the manner 
previously described (section 4.1, page 46). 
Placement of Defibrillation Electrodes 
Dissection was then performed with a cut down to an internal jugular vein using the 
previously mentioned technique (page 46) with the modification described below:  
Using a double ligature technique with ties proximally and a loose tie distally, an 
incision was made into the ventral surface of the vein allowing insertion of two 
identical, dual coil 2.3 mm (7 F, 62 mm RV electrode coil length, surface area = 513 
cm2) active fixation defibrillator leads (Medtronic 6949, MN, USA) via the same vein. 
These were positioned at the RVA and RV outflow tract (RVOT) using fluoroscopic 
navigation (Figure 5.1). Placement sites were randomised for defibrillation testing. 
Fluoroscopy was used after each shock to confirm lead positions. 
Both leads were coupled using a Y-type DF-1 adapter (model 6835, Guidant, Inc., St. 
Paul, MN, USA) during the multi-electrode defibrillation strategy described below. The 
control configuration consisted of a single lead deployed at the RVA plugged directly 
into the DF-1 port of the ICD.  
A standard ICD (model 7274, Medtronic, Inc., MN, USA), with plugged atrial and SVC 













Defibrillation Protocol Design: 
The configuration of ICD (+) > single RVA lead (-) served as the control defibrillation 
vector. Ventricular fibrillation (VF) was induced by administering 5 seconds of 50 Hz 
burst pacing or with a 1J T wave shock. The DFT was determined using a binary 
method with a three-stage reversal (Figure 5.2). 
The shock waveform was non programmable with a 50% / 50% tilt phase duration 2.8 
ms / 2.7 ms in the ICD and therefore standardised for this experiment.  
Rescue shocks were delivered using maximal discharge from the ICD or via a 
transthoracic biphasic shock from an external defibrillator. 
In the test configuration, a second identical active fixation defibrillator lead (model 
6949, Medtronic, Inc., MN, USA) was then employed in the defibrillation circuit. Both 
defibrillator leads were coupled using a Y-adapter as mentioned above. Thus both RV 
electrodes on the leads had the same polarity (-). The second electrode position was 
randomised between either of the RVA or the RVOT. The defibrillation vectors 
employed were ICD (+) > RVA+RVA (-) and ICD (+) > RVA+RVOT (-) respectively 
(Figure 5.1).  
Defibrillation tests were repeated for both these test configurations. The distal 
electrodes were cathodal in all shock configurations used. The order of testing was 
randomised. A 31J (maximal device output) shock was regarded as a failed 
defibrillation attempt. The average of the two lowest energies used to achieve 












The lead positions were rechecked after delivery of each shock with fluoroscopy to 
identify possible dislodgement before the next VF induction and defibrillation. 
 
Statistical Analysis 
A Kolmogorov-Smirnov test revealed non-parametric data distribution. 
The data for each individual lead configuration was compared using a Wilcoxon 
signed-ranks test. A Spearman correlation was also performed on the measures of 






















































Refer to legend on page 84.
A 
Single defibrillator lead at the RV 
apex 
B 
Two active fixation 7F defibrillator leads 
placed at the RV apex 






































Figure 5.1  
 
Fluoroscopic images of RV electrode positions:  
 
A. Single RV electrode at RV apex 
 
B. Two RV electrodes coupled at the RV apical location both cathodal  
  
C. RV electrodes separated to RVOT and RV apex but both coupled together as 
 a cathode using a DF-1 adapter at the ICD port. 
 
C 
Active fixation RV 




ICD located in a left precordial 
subcutaneous pocket 
Active fixation RV defibrillator lead 

























Figure 5.2  
 













The study was conducted in 8 anaesthetised female pigs (21.5 ± 1.2 kg). Lead 
positioning at both the RVA and RVOT were guided by R wave amplitude and pacing 
thresholds. 
Mean R waves recorded at the RVA were 8.3 ± 2.3 mV in the control experiment.  
For the second electrode the mean R waves measured were 7.9 ± 0.05 mV at the 
RVA and 8.3 ± 5.7 mV at the RVOT (p = NS). Pacing thresholds for endocardial RV 
sites were regarded as acceptable if they ranged between 0.5–2.0V at 0.5 ms as 
these served as a surrogate marker for electrode-myocardial apposition. 
The results from the use of a second electrode in the RV at either location (RVA+RVA 
/ RVA+RVOT) were combined. Both these combinations are collectively referred to 
here as the multi-electrode strategy (MES). The lowest defibrillation energy for either 
of the electrode combinations was recorded as the DFT for the MES.  
The accompanying impedances were also recorded for this group. 
A maximum of 18 shocks were delivered in each animal studied taking into account 
rescue shock deliveries as well. Mean VF durations were 9.7 ± 3.4 sec and 9.9 ± 3.0 
sec (p = NS) for the control and MES.  
The MES (RVA+RVA / RVA+RVOT), achieved a reduction in shock impedance (mean 
reduction 13%, range 5–28%; p < 0.01) against control (single RVA electrode) when 



































Figure 5.3  
















































control 6.0 8.0 20.0 20.0 11.0 12.0 20.0 6.0
MES 7.0 8.0 15.0 18.0 8.0 9.0 10.0 6.0
change 1 0 -5 -2 -3 -3 -10 0




Figure 5.4  
Effect on DFTs of an additional RV electrode in RVA or RVOT locations (MES).  













In terms of defibrillation energy requirements, there was an average 25% (range 3–
50%; p = 0.1) reduction in DFTs obtained in 5/8 (62%) cases (second electrode 
locations: RVOT n = 3; RVA n = 2) and equivalent thresholds in 2/8 (25%) subjects 
(Table 5.1).  
There was an increase in DFT energy in one case in the MES and this increase 
measured 3 J for the RVA+RVA configuration and 1 J for the RVOT+RVA 
combination. There were also no significant differences in DFTS or impedances 
between each of the two electrode configurations (RVA+RVA vs RVOT+RVA) (p > 
0.05) but a positive linear correlation was demonstrated between these sites for both 
parameters (Figure 5.5). 
When comparing the control group against the combined test sets (i.e. the MES), a 
significant correlation between DFTs and impedances was noted (p< 0.01 and            
p < 0.01, respectively) (Table 5.2).  
Correlations of DFTs in the control and MES groups against animal weight were also 
evaluated as an increase in body mass index has previously been shown to reduce 
defibrillation efficacy88. A smaller increase in DFTs was observed in the MES with 
corresponding increasing weight in the pigs as compared to the control (i.e. a single 
RV electrode) (Figure 5.6). Therefore, the use of 2 electrodes seems to result in a 



















                            
Experiment Control RVA+RVA RVOT+RVA
1 7.0 9.0 7.0
2 8.0 9.0 8.0
3 20.0 20.0 15.0
4 20.0 18.0 30.0
5 11.0 8.0 14.0
6 12.0 16.0 9.0
7 20.0 20.0 10.0
8 7.0 10.0 7.0
1 44.8 40.0 35.6
2 49.5 45.0 47.0
3 47.3 43.3 43.3
4 46.8 40.8 33.5
5 50.3 46.5 47.5
6 45.5 36.4 37.3
7 48.0 39.0 40.8








Table 5.1  
 







































































Figure 5.5  
Correlation of DFTs and impedances between RVA and RVOT locations (MES) 
rs = +0.455, N = 8, p = 0.257 


















       
Experiment DFT (J) Impedances (Ω) DFT (J) Impedances (Ω)
1 7.0 44.8 7.0 35.60
2 8.0 49.5 8.0 47.00
3 20.0 47.3 15.0 43.30
4 20.0 46.8 18.0 40.80
5 11.0 50.3 8.0 46.50
6 12.0 45.5 9.0 37.30
7 20.0 48.0 10.0 40.80






Table 5.2  
 
























































Figure 5.6  
 
DFTs correlated against weight variation for control and MES in each pig. 
 
rs= +0.441, N = 8, p = 0.274 













The implantation of two defibrillation electrodes within the RV at either an RVA or 
RVOT location resulted in reduction in shock impedances but this phenomenon 
was not consistently accompanied by a decrease in overall DFTs. 
Even though the surface of the cathode was doubled, the change in impedance 
was statistically significant but not proportionate. This means that the coil surface 
is not the only contributor to improved current flow and defibrillation energy 
delivery to myocardium. Singer and colleagues, using a combination of 
endocardial electrodes at the RVOT and RVA and a cutaneous apical patch, also 
showed a non-significant trend to DFT reduction in dogs89. They postulated that 
the wider endocardial coil separation enhances voltage gradient and current 
dissipation to the fibrillating myocardium. 
The critical mass hypothesis postulated by Zipes et al. suggests that successful 
defibrillation is dependent on exposure of a specific amount of fibrillating 
myocardium to shock delivery90. The data arising from this study is supported by 
this concept but it further postulates that changes in defibrillation pathways (i.e., 
vectoral alteration posed by multi-site electrode defibrillation within the RV) also 
has an effect on lowering DFTs.  
It therefore seems intuitive that by just increasing the myocardial exposure to 
twice the number of electrodes, a similar benefit may be obtained. This was not 












However, a significant decrease in defibrillation impedances during MES shocks 
was noted. This reflects optimal endocardial defibrillator lead design technology 
where a maximal electrode surface area is obtained from the coiled nature of the 
defibrillation electrode around the body of the lead maximising energy delivery to 
the myocardium.  
Defibrillation efficacy has not been shown to be impaired by the placement of a 
defibrillator lead in the RVOT in a clinical context91. 
In this study, defibrillation efficacy as well as sensing and pacing parameters 
from the RVA and RVOT were equivalent.  
Lead positioning in the RVOT posed minimal technical challenge. This however 
may have been facilitated by the 7F lead design of the defibrillator leads used 
(Medtronic Inc. 6949 dual coil defibrillation leads, Medtronic Inc. MN, USA). 
The 2.3 mm diameter defibrillator leads used here, theoretically provide less 
obstruction to blood flow and disruption to the tricuspid valve function, making 
this strategy a reasonable consideration in a clinical setting.  
Currently, the 6949 model lead used has been withdrawn due to an unacceptably 
high fracture rate.92 This has been attributed to long-term stress and fatigue on 
the pace/sense wire within this multi-lumen lead.  
There has also been an association of a greater incidence of lead fractures in 












increased torque and stress at the lead tip-myocardial interface with more 
vigorous cardiac contraction93. Alternative 7F defibrillator lead technology is 
available from other manufacturers. 
An active Can electrode to RV coil vector was used with the SVC excluded from 
the circuit. It proved difficult to maintain an optimal intra-thoracic placement of the 
SVC coil in the small thorax of the pig hence this electrode was omitted. 
Furthermore, the use of a dual coil lead instead of a single RV coil has not been 
shown to offer a dramatic advantage in terms of defibrillation efficacy26. 
Nonetheless, it has become common clinical practice to implant dual coil leads. 
There may also be an advantage when attempting an extraction of a single coil 
lead, as there would potentially be fewer adhesions around an SVC electrode.  
The distal ventricular electrodes were cathodal for all configurations tested, as 
this study was conducted prior to change in current conventional shock 
programming. This polarity has recently been shown to be less efficient 
prompting motivation for the distal ventricular coil to be designated as anodal 
during the first phase of a biphasic shock45. A cathodal ventricular electrode 
results in marginal activation, generation of further VF wavefronts and greater 
destructive electroporation of surrounding myocytes. By doubling the number of 
cathodal ventricular electrodes in this study, this deleterious effect potentially 
could have been compounded. Polarity, however, is a programmable option in 
ICDs and this can be easily adjusted to optimize defibrillation efficacy in the 
clinical setting. For the purposes of this study and data interpretation, the shock 













The limited sample size in this pilot study may have resulted in insufficient power 
to show statistical differences in defibrillation thresholds in the MES and control 
groups, although a trend to a reduction in DFTs was noted. The placement of the 
RVOT electrode was also limited by access to the high RV septum in the pig. 
The porcine heart occupies a more central position in the chest and a straighter 
longitudinal cardiac axis than is seen in the human heart94. This impeded 
accurate fluoroscopic placement of a second lead onto the RVOT septum. In 
addition, the circular structure of the pig’s chest wall varies from humans in that 
the antero-posterior diameter of the chest wall in man is smaller compared to the 
transverse diameter. The ICD precordial position is therefore an inaccurate 
comparison to the pectoral position in patients. 
Insertion of a second defibrillator lead into the RV is a feasible option given the 
ease that this can be accomplished surgically. Other interventions, such as 


















The use of an MES comprising two RV defibrillator electrodes coupled together 
at RVA and RVOT locations resulted in equivalent DFTs overall. There was a 
consistent and significant reduction in shock impedances in the MES strategy. 
However, a trend to DFT reduction was noted in 88% of the MES cases. Thus, a 
double RV lead strategy may be a consideration in individual patients presenting 
with compromised DFTs in order to avoid other complex surgical interventions 
such as subcutaneous array placement.  
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6. Transthoracic Defibrillation Studies 
6.1 Comparison of Endocardial and Subcutaneous Defibrillation in a 
Porcine Model. 
Introduction 
Transthoracic defibrillation (TDF) is a useful strategy in a clinical setting as an 
adjunct to impaired defibrillation or where there is limited venous access96. 
Alternatively, it may be the primary option in children or in congenitally and 
surgically altered cardiac anatomy when intravenous leads are best kept to a 
minimum or avoided altogether97. Extra-cardiac defibrillation thresholds are, 
however, higher than in an endocardial system98. This has not been quantified 
and the influence of weight with TDF has not been previously documented. We 
compared defibrillation thresholds (DFTs) from endocardial (EDF) vs TDF in a 













Animal Selection and Preparation  
This experiment was conducted in 9 juvenile female Landrace pigs weighing 20.9 
± 0.7 kg.  
The animals were pre-medicated and anaesthetised according to the method 
previously described in Section 2. A cut down to the left internal jugular vein was 
performed and a 2.3 mm (7F) ventricular defibrillation lead (model 6949, coil 
length 6.2 cm, surface area = 513 mm2) was inserted. The electrode was 
transvenously positioned at the RVA under fluoroscopic guidance. Adequacy of 
the electrode position was assessed using pacing thresholds and R wave 
sensing parameters. An R wave electrogram amplitude of ≥ 5mV and a pacing 
threshold of < 1 V @ 0.5 ms were accepted. 
A subcutaneous single finger array (SQA = Medtronic 6996, coil length = 25 cm, 
surface area = 500 mm2) was positioned around the left chest wall directly 
posterior to the middle of the cardiac silhouette on fluoroscopy, relative to the 
major myocardial bulk. 
The array was inserted using a tunnelling tool on which a split-able sheath was 
mounted. The tool was burrowed from the left precordial pocket fashioned to 
house an ICD, around the left chest wall to lie posterior to the cardiac silhouette 












attained, the radio-opaque tunnelling tool was withdrawn and the SQA was 
advanced through the sheath.  
The sheath was then withdrawn and split over the lead leaving the array in place. 
The final SQA position was confirmed on fluoroscopy before being connected to 
the ICD. 
A standard dual chamber ICD with capped atrial and SVC ports (Medtronic Inc., 
Marquis DR 7274, surface area = 66 cm2) was used in the experiment.  
The ICD was implanted into a low precordial subcutaneous pocket overlying the 























Figure 6.1.1A  
A coronal view of ICD and SQA placement: 
Showing the position of the ICD in a low precordial subcutaneous pocket 
with a single finger subcutaneous array placed subcutaneously around 






























A sagittal view of ICD and SQA placement: 
Showing the location of the ICD and SQA in relation to the 















Group 1 of the experiment entailed determining the EDF threshold. The distal RV 
coil was connected to the DF-1(-) port of the implanted ICD and the same  
3-reversal binary up/down algorithm (Figure 6.1.2) was used to obtain a DFT in 
an ICD (+) > distal coil (-) shock configuration for both EDF and TDF.  
For group 2, this distal RV defibrillator coil was disconnected; however, the 
pace/sense component of the endocardial defibrillator lead was left in place for 
VF induction and sensing functions through the ICD. Instead, the posteriorly 
located, distal SQA (cathode) was inserted into the DF-1(-) port. The defibrillation 
protocol above was repeated. A 30J shock was regarded as an impaired/high 
DFT since a 10J safety margin from the maximum output of the implanted device 
(30 J) could not be assured. The order of testing between the 2 groups was 
randomised. 
VF induction was performed either by a 50Hz burst pacing for 5 seconds duration 
or with a 1J T wave shock delivered through the implanted ICD as previously 
described.  
Rescue shocks were delivered for failed defibrillation as a 30J endocardial 
delivery from the device or alternatively a 200J biphasic external thoracic shock. 
A 3-minute interval between each induction and defibrillation was observed or 






























Figure 6.1.2  
 
The Binary up/down defibrillation search. 
 
This schematic depicts the protocol employed for defibrillation testing 
  













All data were collated into an Excel spreadsheet and then imported into SPSS 
statistical package for further analyses. The mean ± standard deviation and 
range were used to represent the defibrillation parameters. 
A one-sample Kolmogorov-Smirnov test was applied to the data confirming a 
normal distribution of the DFT results. 
A paired t-test was used to determine statistical significance between the groups 
and a Pearson’s correlation was performed to demonstrate relationships in the 













A mean DFT of 12.1 ± 5.2 (range 6.0–20.0) joules (J) and 22.8 ± 6.9 (range14–
30) J was demonstrated for EDF vs. TDF (p < 0.01). 
An impaired/high DFT of ≥ 30 J was identified in 3/9 (33%) pigs in the TDF group 
and none in the EDF group. 
A summary of the DFTs for groups 1 and 2 is represented against weight in a 
linear graph in Figure 6.1.3. 
The weight of the animals was correlated against the DFT for EDF (group 1) and 
TDF (group 2). This correlation was significant for both EDF and TDF with 
measured values of r = 0.695, N = 9, p = 0.04 and r = 0.756, N = 9, p = 0.02 for 
each of the groups respectively (Figure 6.1.4). A Pearson correlation, performed 
to compare the DFT results in both groups, is illustrated in Figure 6.1.5. This, 
however, did not demonstrate significance but there is an appreciable linear 
relationship between both groups with increasing weight except for an outlying 


































Figure 6.1.3  
A linear graph summarising DFTs in groups 1 (EDF) and 2 (TDF). 















Figure 6.1.4  


















Figure 6.1.5  













Transthoracic defibrillation in combination with endocardial electrodes is an 
effective strategy to enhance defibrillation efficacy96.  
This may not be preferred as a sole strategy in a clinical setting because of the 
high defibrillation energies required. However, it may be a consideration in 
children or adults of low BMI given the evidence from the above results99. 
This investigation demonstrated a statistical difference (p < 0.05) of EDF vs TDF 
DFTs, with the former having a far better defibrillation success rate. Defibrillation 
testing in a clinical setting typically tries to insure a 10J safety margin from the 
maximum output of the device in a clinical setting.  
Therefore, a DFT of 30 J (the maximum stored energy of the device used in the 
experiment) was regarded as impaired or a high DFT as 33% of the animals in 
the TDF group were noted to fall into this category and none in the EDF group. 
This observation was made without apparent differences in shock impedance or 
VF duration (p = 0.6 and p = 0.2 respectively) between the TDF and EDF groups. 
A higher shock impedance was expected on the TDF strategy given the 
intervening tissue and lung volume between the active Can and SQA electrodes, 
but these differences were marginal [43.6 ± 10.3 ohms (Ω) for TDF vs 42.8 ± 9.8 
Ω for EDF, p = NS]. This finding may be partly explained by the limited weight 
and size of the pigs chosen, but it also reflects the technology and design of the 












The model 6996 single finger array (Medtronic Inc. MN, USA) has a 25 cm coil 
length with a total surface area of 500 cm2. 
Subcutaneous array lead placement using the tunnelling tool was performed with 
ease in all cases. This also relates to the fact that the procedure was being 
undertaken under general anaesthesia. This is not the standard for transvenous 
ICD implantation in all centres, as conscious sedation poses a cost and 
convenience advantage. Subcutaneous array placement with conscious sedation 
may not be comfortable for the patient. However, whenever the clinical setting 
warrants, e.g. paediatric patients, it is conceivable that general anaesthesia 
would be preferred. 
In this experiment, 33% of the pigs had an impaired/high DFT classified as ≥30J, 
i.e. the maximum delivered energy of the ICD used. We therefore suggest that 
higher energy devices are indicated when considering a TDF strategy in clinical 
practice.  
Alternative strategies to deal with high DFTs include the addition of extracardiac 
electrodes. These measures include the addition of an SVC coil into the azygous 
vein in patients with high DFTs95. Surgical placement of a defibrillator lead into 
the transverse sinus in the intrapericardial space has been safe and effective in a 
series of seven children100. Inadequate venous access in the case of vein 
stenosis sometimes dictates the need for alternative lead placements. Minimally-
invasive thorascopy-assisted epicardial defibrillator lead placement has also 













The obvious limitation in this study is the small sample size of just nine pigs. 
Furthermore, the distance between the SQA located on the posterior chest wall 
and the endocardial RV electrode was not recorded. Apart from the increase in 
animal weight, the increase in chest wall diameter may have been a factor given 
that the separation between electrodes may have been disproportionately greater 
in the larger pigs, increasing the interposed tissue within the shock vector and 
thus contributing to impaired shock efficacy.  
The narrow weight variation in the pigs does not parallel the variation we find in 
clinical subjects. This, however, was intentional to keep a relatively narrow 
weight range for other concomitant defibrillation studies as animals were reused 
in experiments in keeping with a prescribed policy of “reduction” in animal usage. 
Nevertheless, it highlights the sensitivity of TDF to weight variations. 
Conclusion  
As expected, a TDF strategy was less efficient than EDF in this porcine model. 
Despite a narrow weight variation, an impaired or high DFT result was observed 
in 67% of TDF attempts and a positive correlation with weight in both groups. 
The TDF strategy was more sensitive than EDF to minor variations in animal 
weight, suggesting that high energy ICDs should be favoured for a TDF. Despite 
the variation in DFTs, there was little change in impedance values between TDF 












6.2 The Influence of Combined Subcutaneous Arrays on Defibrillation 
Outcome. 
Introduction 
Although the addition of an SQA may enhance endocardial defibrillation efficacy, 
a stand-alone TDF is characterised by higher DFTs than endocardial electrode 
placement as was demonstrated in the preceding section98;101. The optimum 
SQA electrode configuration and polarity for TDF is not known.  
In this study, the single SQA was compared with a combination of 2 SQAs 
located at 2 positions on the dorsal surface of the pig. This was performed to 














Animal Selection and Preparation 
This study was conducted in 6 closed chest female Landrace pigs. 
A cut down was performed to the left internal jugular vein and a 7F dual coil 
defibrillator lead (model 6949, coil length 6.2 cm, surface area = 513 mm2, 
Medtronic Inc, MN, USA) was inserted and advanced under direct fluoroscopy to 
the ventricular apex. 
A single finger SQA (25 cm coil, Model 6996 Medtronic Inc.) was tunnelled along 
the thorax, along an intercostal space to lie posterior to the cardiac silhouette on 
fluoroscopy (refer to the method previously described in section 6.1 page 100–
101). The SQA was cathodal (-) in the shock configuration. 
The ICD Can electrode (Medtronic 7274 dual chamber device with plugged atrial 
and SVC port) was implanted into a low precordial, subcutaneous pocket on the 
chest wall overlying the major ventricular mass as previously stated in 6.1 (page 
114). A second identical SQA was then positioned within 1 cm of the first array; 
evident on fluoroscopy at position1 (P1) and both arrays were coupled with a Y-
adapter to the distal unipolar defibrillation port of the device, i.e. both SQAs were 
designated cathodal.  
Thereafter SQAs were then separated by ±10 cm to approximate the upper and 
lower extents of the cardiac image on fluoroscopy. This entailed the next test 




















Figure 6.2.1  
Cartoon of experimental configurations of SQA positioning 
A. Configuration 1 - Sagittal view showing the low precordial Can position 
with a single SQA positioned posteriorly.  
 
B. Configuration 2- Two identical SQAs combined as cathode in position 
P1 immediately posterior to the cardiac silhouette on the thorax ± 1 cm 
apart.  
 
C. Configuration 3 - The second SQA moved ± 10 cm superiorly on the 















Defibrillation testing was conducted using a Can>SQA shock vector and a 3-
reversal up/down binary search (as depicted in Figure 6.1.2 on page 105). The 
lowest energy obtained was regarded as the DFT for that particular configuration. 
This was done to reduce the number of VF inductions and shocks in the animal. 
Ventricular fibrillation was induced by 50Hz burst pacing or T wave shock 
through an RV apical, endocardial lead connected to a 7274 ICD (Medtronic Inc., 
MN, USA). 
Defibrillation threshold testing was repeated using the method mentioned above. 
A DFT of ≥ 30 J was regarded as an impaired or high DFT since a 10J safety 
margin was not attained. A 3-minute rest period was allowed between VF 
inductions to allow the recovery of the blood pressure and HR to baseline. The 













The study was conducted in 6 anaesthetised female pigs weighing 20.8 (range, 
20–23) kg. The mean blood pressure recorded was 44.1 (range, 27.4–82.8) 
mmHg and mean HR 108.2 (range, 96.3–176.8) beats per minute. 
This study did not show any significant effect on DFTs by the addition of a 
second SQA, either at a combined location or with an altered vector arising from 
SQA separation (p = 1, p = 0.8, respectively) (Table 6.2.1 and Figure 6.2.2). 
However there was a trend to lower DFTs with the configuration 3 arrangement 
of SQAs (p=NS). 
Overall impedances, however, were significantly lower with combined SQAs. 
This is reflective of the increased surface area presented by linking both of these 
















 Configuration1 Configuration2 Configuration3 
        
DFT Mean DFT 20.7 20.7 20.4 
 std dev 6.3 6.1 6.7 
     
     
Impedance Mean Imp 48.1 42.7 41.0 
 std dev 2.4 10.4 7.2 
     
VF 
duration Mean dur 16.0 12.9 9.7 
 std dev 5.7 5.3 2.3 
     
 
Table 6.2.1  


















Figure 6.2.2  


















Figure 6.2.3  













Although transvenous defibrillator systems are now the cornerstone of ICD 
management, they are by no means absolute. The complications related to 
transvenous systems are also not trivial. Limited venous access related to the 
age of the patient or anatomical hindrances show the advantage in having 
extracardiac or subcutaneous ICDs102;103.  
The totally subcutaneous ICD system as proposed by Cameron Health shows 
promise104. There are randomized controlled trials underway that assess the 
subcutaneous system directly against transvenous systems105;106. This system is 
conceivable for patients who do not require bradytherapies or ATP. The clinical 
configuration utilizes an axillary ICD placement that can be cumbersome. The 
configurations explored in this chapter illustrate an effort to maintain a traditional 
prepectoral Can position for an entirely subcutaneous ICD implantation.  
Combining SQAs in a posterior/dorsal location in a TDF did not significantly 
affect defibrillation efficacy. A further separation in the leads resulted in a 
marginal 0.1% reduction in the mean DFT (configuration 3).  There was a more 
substantial decrease in defibrillation impedances by adding 2 SQAs.  
The reduction in impedance that was observed may imply improved current 
delivery through the chest wall to the underlying fibrillating myocardium; however, 
this was not reflected in the DFTs. The vectoral variation created in configuration 
3 showed a trend to DFT lowering as compared to the closely set SQA pair seen 












It is unlikely that there was current shunting in configuration 2, as the impedance 
values in configurations 2 and 3 were comparatively similar. It therefore seems 
more likely that the DFT change was truly due to the minor vectoral change 
afforded by electrode separation on the dorsal wall of the animal. 
The overall non-superiority of combining electrodes indicates, however, that 
using multiple SQAs contributes little to enhance TDF. 
Long term stresses and tolerance on these subcutaneous leads need to be 
investigated in a clinical setting. There was relative ease of implantation with use 
of the tunnelling tool in the animals bearing in mind this was also performed 
under general anaesthesia. 
Limitations 
This again was a small study consisting of just six pigs. The overall distance 
between the SQAs and the heart was not recorded in this study but was unlikely 
to be altered by just increasing the number of electrodes. This, together with 


















 In a TDF strategy, the use of a single finger cathodal SQA situated in a dorsal 
thoracic site with a precordial ICD, was as effective as combining two SQAs in 
various dorsal locations. A drop in defibrillation impedance was noted with the 
combination of two arrays but this did not influence the defibrillation threshold. 
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6.3 The Effect of an Extended Anterior Chest Wall Anodal Electrode in a 
Transthoracic Defibrillation Model. 
Introduction 
In the preceding chapter, I examined the influence of an increased cathodal 
surface area in an antero-posterior TDF format. Recent studies have proposed 
that a reversed RV anode > ICD Can cathode defibrillation is more effective with 
endocardial lead placement45. In this section, the anodal electrode surface was 
extended using an experimental 15cm single-finger SQA to enhance the anodal 
(+) polarity dominance during TDF in order to assess the effect on defibrillation 
efficacy. 
An antero-posterior chest wall electrode configuration consisting of an anteriorly 
located active Can electrode with a posteriorly implanted single finger SQA has 
been proven to be effective in anecdotal clinical scenarios99;107;108. 
Here, I investigated the effect of increasing the anterior chest wall subcutaneous 
electrode area by implanting an experimental, 15cm single-finger array (6996s. 
Medtronic Inc., MN, USA) at a parasternal location and designated this electrode 













Animal Selection and Preparation 
The study was conducted in 6 anaesthetised female Landrace pigs (average 
weight 20.8 ± 0.7 kg). An ICD was placed in a precordial subcutaneous pocket 
and connected to a single-finger subcutaneous 25 cm coil electrode (model 
6996, Medtronic Inc.), which was tunnelled horizontally around the left chest wall, 
posterior to the cardiac silhouette on fluoroscopy using the previously described 
technique (page 100–101). This electrode was not located to a specific 
interspace, but an attempt was made to have the major myocardial mass located 
between the anterior chest wall electrodes and this single, posteriorly located 
SQA using fluoroscopy. 
A 15 cm experimental SQA (exSQA = model 6996s, Medtronic Inc.) was then 
implanted subcutaneously to lie parallel to the right parasternal edge with 
intervening tissue separating it from the implanted precordial ICD (Can 
electrode). The shorter lead design allowed easier lead positioning, particularly in 
the smaller size pigs chosen for the experiment. A standard pace/sense lead was 
endocardially positioned at the RVA for induction and sensing and back up 
pacing (method described on page 60). This was connected to the IS-1 pacing 













The additional exSQA was connected to the SVC port (+) of the device. The 
active Can (ICD) and exSQA were therefore coupled together as a combined 
anterior chest wall anode. A Can > posterior standard SQA (pSQA) was used as 
the control while the Can + exSQA > pSQA was the test configuration. 
Ventricular fibrillation was induced with 50Hz burst pacing or a T wave shock 
delivered via a right ventricular pace/sense lead implanted transvenously and 
connected to the device. Defibrillation threshold testing was conducted using a 3-
reversal Binary protocol (Figure 6.1.2 on page 105). The average of the two 
lowest energy achieving defibrillation was regarded as the DFT. The order of 
DFT testing was randomised between control and test configurations. Rescue 













Placement of the additional parasternal anode-electrode resulted in a significant 
rise in DFTs from control (p = 0.04) (Table 6.3.1, Figure 6.3.1). The mean rise in 
DFT = 4.7 ± 3.3 J with 66% (4/6) cases in the test group having a defibrillation 
requirement of ≥ 30 J; i.e., the maximum output of the ICD. A drop in shock 
impedance was a consistent observation when the additional exSQA was used 
(mean decrease = 14.6 ± 3.2 Ω; p = 0.001, Figure 6.3.2). The longer VF time 
(average difference = 12.5; range 1.5–30 sec) in the test group reflects the 
overall VF duration and includes initial failed attempts. The fact that more initial 















 Control Test 
 Can(+) > pSQA Can + exSQA > pSQA 
DFT (J) 21.7 ± 6.4 28.0 ± 4.0 
Impedance (Ω) 43.6 ± 10.3 33.2 ± 3.9 
VF time (s) 16 ± 5.7 29.9 ± 16 
 
 
Table 6.3.1  



















Figure 6.3.1  
Comparison of mean DFTs in control and test groups.  
Bar graph of the mean DFTs in each group with indicated standard error,    




















Figure 6.3.2  
Summary of mean impedances in control and test groups. Mean impedance 
difference between test and control groups with indicated standard error,   













The addition of an experimental 15cm SQA in a left parasternal location resulted 
in a 29% increase in DFTs compared to a standard antero-posterior transthoracic 
defibrillation vector. 
The reduction in defibrillation impedances may reflect current shunting between 
the Can and exSQA electrodes. This may also explain the reduced defibrillation 
efficacy. This phenomenon occurred despite the care exercised to maintain 
adequate separation between both (Can and exSQA) of these electrodes.  
Despite the disappointing defibrillation outcome, the reduced length of the 
exSQA presented ease of manipulation together with the use of a shorter 
tunnelling tool. Placement in the parasternal region requires a shorter coil length 
array which is the same in human subjects, particularly with children in whom 
TDF would be an option. A 25 cm coil would result in increased tissue 
manipulation, operative morbidity and possibly redundant coil exposure risking 
encroachment into the ICD pocket. 
A low precordial subcutaneous, ICD pocket has been shown to be 
advantageous, not only from TDF efficacy perspective, but is also cosmetically 
















The need to add an SQA in a clinical setting as an adjunct to endocardial 
defibrillation is infrequent and this then brings into question the relevance of this 
study. However, subcutaneous and “leadless” ICDs are increasingly topical, 
particularly with the increasing use of ICDs in the paediatric population98;110;111. 
The use of shorter SQAs potentially reduces trauma to tissues during 
implantation. It is then also useful to determine which SQA positions are 
beneficial, but also to determine configurations that should be avoided, as is 
highlighted by this experiment. 
Conclusion 
Addition of a short (15cm) subcutaneous array (exSQA) at a parasternal location 
increases the anterior anodal electrode surface area but reduces defibrillation 
efficacy. This may be because of current shunting between the Can and SQA 
despite their equal polarities and is reflected by a reduction in shock impedance. 
The clinical implication is therefore not to position additional SQA electrodes on 
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7. A Pilot Project to Assess Defibrillation from an Intrapericardial Location. 
Introduction 
In a clinical setting, failed defibrillation may present a challenge to adapt the 
defibrillation circuit to enhance efficacy. In this thesis I have expanded on 
waveform manipulation and the use of additional endocardial leads, as well as 
the inclusion of SQAs. Each of these options has yielded marginal benefit 
beyond conventional techniques. The pericardial space presents an attractive 
option for lead placement. This region can be accessed using percutaneous 
methods. It allows direct contact of electrodes with the ventricular epicardium 
thus minimising the amount of interposed bystander tissue within a shock vector. 
Percutaneous intrapericardial delivery of a standard ICD lead has been 
demonstrated anecdotally112.  
This study was a pilot project to assess the feasibility of percutaneous delivery of 
conventional defibrillation leads designed for transvenous placement into the 
pericardial space and to assess their performance in terms of defibrillation 
efficacy. This was compared against endocardial and subcutaneous defibrillation 













Animal Selection and Preparation 
The study was conducted in 4 female pigs of the Landrace variety with a mean 
weight of 20.6 ± 1.0 kg. Each animal was anaesthetised using methods 
previously elaborated on (chapter 2 on page 38).  
A 18G Tuohy needle attached to a 10cc syringe containing a 1:1 mixture of 
sterile 0.9% saline and iodine based radio-opaque contrast was advanced under 
fluoroscopic guidance from the sub-xiphisternum at a 30–45° angle aiming 
cranially aligned  with the longitudinal axis of the sternum (Figure 7.1).  
On entering the pericardial space, an injection of the diluted contrast was injected 
creating a meniscus around the lower cardiac silhouette on fluoroscopy. A 
flexible J-tip 0.38 inch, 50 cm guide wire was then advanced through the hollow 
needle into the pericardial space. 
Care was taken to loop the guide wire in the pericardium and to insure that it 
passed freely in all planes, confirming this in an AP and LAO projection. Once 
this was done, a 7F splitable sheath (Sorin Biomedica, TFX Medical, Annacotty 
Ind. Estate, Limerick, Ireland) was advanced over the wire. The introducer was 
then withdrawn and occluded in order to minimise air entry into the pericardium. 
A TransveneR SVC unipolar defibrillation electrode (model 6937 Medtronic Inc., 
coil length 8 cm, 160 mm2, 2.3 mm tip diameter and 1.8 mm shaft diameter) was 














Figure 7.1  
AP and LAO projections of entry into the pericardial space. 
 
A. Entry of a bevelled needle from a sub-xiphoid approach with entry 
into the pericardial space. A meniscus of injected contrast 
identifies the intra-pericardial space seen in AP projection. 
 
B. A single coil transvene SVC defibrillator coil is then passively 
inserted through a guide sheath into the posterior pericardial 














The coil orientation was vertical, corresponding to the longitudinal cardiac axis 
and this was left passively in place for the duration of the experiment. The 
position was confirmed in antero-posterior and left lateral oblique views and 
periodically confirmed on fluoroscopy through the experiment. An effort was 
made to keep the PPS lead position constant but variability was inevitable 
because of the lack of a fixation mechanism and also as the position was 
dependent on the access point into the pericardium. 
This electrode was connected to the DF-1 distal (-) port of a standard dual 
chamber ICD (model 7274, Medtronic Inc. with capped SVC and atrial ports, 
except for experiment 3, where the Gem DR model 7271 was used. The device 
was implanted into a low precordial subcutaneous pocket directly overlying the 
cardiac silhouette on fluoroscopy (Figure 7.2). 
In addition, a cut down was performed to the left internal jugular vein and a 
standard single coil defibrillator lead was delivered transvenously to the RV apex. 
A single finger subcutaneous 25 cm coil electrode (model 6996, Medtronic Inc.) 
was tunnelled around the left chest wall, posterior to the cardiac silhouette on 
fluoroscopy (pSQA). These were connected to the ICD in a randomised fashion 




















Figure 7.2  
Sagittal view of the ICD location. 
Reference is given to the intra-pericardial defibrillator electrode, a 
defibrillator lead at the RVA and the dorsally located SQA. 
Active 
CAN/ICD 
Lead in the intra- 
pericardial space 
SQA implanted on 
the dorsal aspect 
of the chest 
Anterior 













Three defibrillation configurations were compared:  
1. CAN > RV apex (endocardial electrode) 
2. CAN > posterior subcutaneous array (pSQA) 
3. CAN > post pericardial space electrode (PPS) 
The order of testing was randomised between each configuration.  
Ventricular fibrillation was induced either with 5 seconds of 50Hz burst pacing or 
with a T wave shock. If both methods failed, the positive and negative terminals 
of a 9V battery were crossed and direct current was applied through the 
pace/sense IS-1 component of the endocardial defibrillator lead. 
Shocks were delivered in the format outlined above through the implanted ICD. 
Rescue shocks were delivered at maximum output from the ICD (30J), failing 
which, a 200J biphasic, transthoracic shock was delivered via an external 
defibrillator. The lowest average defibrillation energy was regarded as the DFT. 
Failed defibrillation was regarded as 30 J (maximum device output). 
Statistical Analysis 
Continuous data is expressed as mean ± SD. Data was collected in Excel spread 














This pilot study consisted of 4 pigs with a mean weight of 20.6 kg. 
Instrumentation and pericardial lead placement times varied between 10-15 
minutes. No animals were lost from pericardial access or lead placement or from 
pericardial tamponade.  
Defibrillation outcomes are shown in Figure 7.3. The mean DFT and impedances 
in RVA, SQA, and PPS were: 9.0 ± 4.1 J, 46.8 ± 2.5 Ω; 20.3 ± 7.3 J, 49.3 ± 1.9 Ω 
and 16.5 ± 9.6 J, 66.7 ± 29.5 Ω, respectively.  
The PPS defibrillation system displayed equivalent DFTs to the endocardial 
system in experiment 1. However the remaining 3 experiments displayed 
equivalence to the SQA system which was characterised by higher DFTs. The 
overall impression was that there was no significant change between the SQA 
and PPS configurations although a trend to DFT reduction was observed in the 
latter. There was a 19% reduction in the mean DFT between the SQA 
configuration and the PPS.  























































Figure 7.3  
Comparison of DFTs and impedance values from RVA, SQA and 
PPS systems.  
 A. Bar graph of DFTs in each experiment 













This pilot set of 4 experiments demonstrated the feasibility and safety of 
percutaneous placement of a defibrillation electrode into the posterior pericardial 
space. Both the PPS and SQA defibrillation systems displayed higher DFTs than 
an endocardial system. However, the PPS defibrillation vector showed a trend to 
greater DFT reduction than the SQA system.  
The abrupt rise in impedances in experiment 3 is most likely attributable to air 
entry into the pericardial space, despite the caution exercised during cannulation 
and access.  
In this set of experiments, a Transvene-SVC electrode, designed for 
intravascular placement was used. It was easily inserted through a sheath into 
the pericardial space but was prone to displacement. Hence, periodic fluoroscopy 
was required to confirm the position of the lead. This would not be reliable in a 
clinical setting. A recent clinical report by Jacob et al. describe a technique 
whereby a loop is created in an SQA (Medtronic 6996 lead) in order to minimise 
movement within the pericardial space112. Defibrillation efficacy was also 
enhanced with this intrapericardial lead configuration in this case report. 
Limitations 
This is a pilot study that addressed the feasibility of percutaneous delivery of a 
defibrillator lead to the pericardium and the efficacy of this shock vector. 












system compared to a subcutaneous or endocardial system. That would require 
a larger study, as well as a custom-designed percutaneous pericardial delivery 
system and lead for epicardial fixation in order to be clinically relevant. 
Conclusion  
Intrapericardial defibrillator electrode placement is feasible using a percutaneous 
approach. It is also shown to be effective and equivalent in some scenarios to an 
endocardial strategy, and perhaps superior to the addition of an SQA when used 
to improve defibrillation efficacy. This approach, however, warrants a custom 
lead design in order to maintain lead position and stability.  
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8. Clinical Evaluation of Implantable Cardioverter-Defibrillator Derived 
Electrograms and Anti-Tachycardia Pacing. 
8.1. The Pause After Anti-Tachycardia Pacing May be a Useful Tool to 
Differentiate Supraventricular and Ventricular Tachyarrhythmias in 
Implantable Cardioverter-Defibrillators. 
Introduction 
Rapidly conducted atrial fibrillation (AF) or atrial tachycardia (AT) is a frequent 
cause of inappropriate therapies (ITS) in patients with ICDs8;113-115.The rate of the 
conducted SVT may exceed the upper rate at which discriminators and 
morphology templates are programmed, leading to inappropriate shocks that are 
usually preceded by an episode of ATP67;116. If the ATP is ineffective in 
terminating the rhythm, the result is in essence a form of manifest entrainment 
from the RV lead pacing site. 
The concept of entrainment has been previously defined as a basic 
electrophysiological manoeuvre to indicate the proximity of a roving pacing 
catheter to a macro re-entrant circuit117;118. These fundamental principles may be 













Given the relative proximity of an RV lead, an entrained ventricular tachycardia 
(from this pacing source), should have a shorter PPI than if the ventricular rate 
was due to rapidly conducted AF/AT. 
Thus, in the case of AF/AT, the pause after pulses of ATP would represent a 
retrograde penetration of the atrioventricular node (AVN) and His-Purkinje 
system accounting for a longer interval after ATP before resumption of antegrade 
conduction of the tachycardia119. 
Methods 
This study was a retrospective analysis of all patients implanted with ICDs for 
combined primary and secondary indications at a single centre. The cohort 
consisted of 250 patients (46 female). These were of mixed ischaemic and non-
ischaemic aetiologies with a mean age of 73 ± 7 years. 
All patients received either dual chamber (DR) or biventricular (BiV) ICDs. 
Patients were excluded if they received single chamber devices or if the atrial 
ports of the devices were plugged. This was done so that only episodes with a 
corresponding atrial EGM would be analysed for proof of concept.  














The clinical records of all patients implanted with DR and BiV ICDs, were 
examined for the period from December 2006 to October 2008. All patient related 
device therapies that were flagged in a database were then re-examined. These 
were then classified into appropriate or ITS. All non-physiological events (“noise 
related events”) and oversensing phenomena were excluded from the analysis. 
Definitions 
The PPI was defined as the first return cycle length after ATP (burst/ramp). The 
PPI -TCL where the tachycardia cycle length (TCL) was the average ventricular 
tachycardia cycle length calculated by the device. The mean cycle length (CL) of 
the tachycardia for analysis was determined as the average of five successive 
CLs, excluding the first interval after the PPI (to allow for minor CL variation after 
ATP) (Figure 8.1.1). 
The mean CL post ATP was compared to the preceding mean CL of the 
tachycardia pre ATP to ensure that there was no significant variation in 






















Figure 8.1.1  
An illustration of the ATP response in an episode of AT. 
The ATP response with PPI and TCL intervals in an episode of AT with a 
rapidly conducted ventricular rate resulting in inappropriately delivered 
ATP by a dual chamber device. The arrows in the atrial EGM show that AT 
cycle length is not advanced by ventricular pacing but “marches” through. 
The AT is ongoing after the ATP and because of the pause seen after 
ventricular pacing, a “pseudo AAV” post ATP is seen. In essence, the 
ventricle was dissociated from the atrium during ATP further confirming 















Exclusion criteria were applied to the remaining data sets to ensure that the 
delivered ATP did not significantly perturb the ongoing tachycardia to account for 
the episode as a single ongoing event: 
1. The post ATP and pre ATP TCL varied > 50 ms if the preceding 
tachycardia was stable, e.g. in VT, AT, or pseudo regularisation of rapidly 
conducted AF. 
2. ATP terminated the episode  
3. A ventricular paced event occurred at the lower programmed rate 
immediately after ATP 
4. ATP accelerated the preceding tachycardia CL by > 50 ms 
All events were evaluated in a standardised manner: 
a. The scatter plot (dot-plot), and local and farfield EGMs were viewed 
collectively to aid diagnosis. 
b. Events were evaluated in chronological order (episode) and then 
sequentially (sequence of ATP) per individual patient.  
c. Each episode was categorised as appropriate or inappropriate depending 

















Ventricular (V) Tachycardia Atrial (A) Fibrillation/Atrial Tachycardia 
Onset of tachycardia in ventricle Onset of tachycardia in atrium 
V rate > A rate A rate > V rate 
A and V dissociation V rate predicted by atrial rate 
Stable V-V relation Number of A events > number of V events 
V–A timing with retrograde conduction Unstable/variable V-V 
 Variable V to A timing 
 
Table 8.1.1  















Patient demographics are represented as mean ± standard deviation. Data was 
analysed and presented using Minitab and SPSS. A t-test was used to assess 
significance and a p < 0.05 was regarded as significant. Receiver operator 
curves (ROC) were used to determine absolute cut-off values that would 













There were 165 DR and 85 BiV ICDs implanted in the cohort. All Medtronic ICDs 
Entrust, Virtuoso, and later models were included because of familiarity of the 
observers with the manufacturer’s method of data representation, allowing 
optimal observer diagnostic capability. 
A total of 39 episodes were identified in 20 patients over a mean follow-up period 
of 23 months. The incidence of delivered therapies was 8% in this population. 
There were 76 sequences of ATP (burst/ramp) delivered in total within these 
episodes.  
Twenty-eight sequences (37%) were categorised as inappropriately delivered for 
either AF/AT. This was observed despite all but one patient having advanced 
discriminators programmed on. All elements of PR logic (Medtronic Inc., MN, 
USA) were selected except for “other 1:1 SVTs”, which is nominally off in these 
devices. 
After applying the exclusion criteria listed above, 51 sequences of ATP (n = 18 
AT/AF, n = 33 VT) were available for analysis. The mean PPI was 693 ± 96 ms 
vs 582 ± 83 ms for VF, p < 0.01 and mean PPI-TCL was 330 ± 97 ms vs 179 ± 


















Figure 8.1.2  
Distribution of data and means using PPI as a discriminatory tool for AF/AT 
and VT. 
 


























Figure 8.1.3  
Distribution of data and means using PPI-TCL as a discriminatory tool for 














A ROC curve was applied to both the PPI and PPI-TCL diagnostic criteria to 
determine an absolute cut-off to that would define VT from conducted AF/AT. 
Cut-offs of 615 ms, AUC 0.93 (95% CI: 0.84–1.00), p < 0.01 for the PPI, and 260 
ms, AUC 0.86 (95% CI: 0.74–0.98), p < 0.01 for PPI-TCL (Figure 8.1.4) were 
identified. 
When applying these two criteria, a PPI < 615 ms predicted VT, rather than 
AF/AT with a sensitivity of 77.8% (95% CI: 58.6–97.0%) and a specificity of 
87.5% (95% CI: 76.0–99.0%). The positive predictive value (PPV) for AT/AF 
detection was 77.8% (95%CI 58.6–97%) and the negative predictive value 
(NPV), i.e. not AT/AF, but VT, was 87.5% (95% CI 76.0–99.0%).  
Furthermore, a PPI-TCL with a value < 260 ms was more likely to be VT than 
AF/AT with a sensitivity of 72.2% (95% CI: 51.5–92.9%) and a specificity of 
78.1% (95% CI: 63.8–92.4%). The PPV was 72.2% (95% CI 51.5–92.9%) for 
AT/AF and the NPV was 78.1% (95%CI 63.8–92.4%), i.e. not AF/AT, but VT 
detected.  
Thus, the predictive value of both parameters had a greater likelihood of 
diagnosing VT than AF/AT, which is acceptable for a default setting within an ICD 
















Figure 8.1.4  
The ROC curves of PPI and PPI-TCL parameters.  
The PPI parameter appears to be more robust with a greater area under the 













Anti-tachycardia pacing has been shown to successfully terminate VT in over 
90% of cases, making this an effective and painless initial therapy in ICDs67. As a 
result, programming strategies usually employ a single sequence of ATP prior to 
delivery of a shock if the tachycardia is classified as stable despite the cycle 
length being recorded in a VF detection interval.  
If ATP fails to terminate the tachycardia, there is usually an escalation in 
therapies to defibrillation. Some manufacturers also resort to committed 
therapies after failure to terminate the episode based on the original diagnostic 
criteria. 
Thus, if there was an incorrect classification of an SVT at the outset, multiple 
inappropriate shocks may be delivered by the device. This problem is more likely 
to occur with single chamber ICDs, where the absence of an atrial lead makes 
diagnosis of VT reliant on rudimentary discriminatory criteria (i.e., rapidity of 
onset and stability of the tachycardia) and in patients with AF120. 
 Some manufacturers also offer a morphology detection algorithm that has been 
shown to reduce ITS, however, this is also prone to errors in sampling121.  
The above-mentioned study analyses the PPI after a failed episode of ATP until 
resumption of sensed ventricular intervals by the ICD. Entrainment of a macro re-













A PPI < 30 ms generally denotes that the pacing stimulus is directly within the 
macro-re-entrant circuit (Figure 8.1.5). This was not the case for cases with VT 
(mean PPI of 582 ± 83 ms) or for AF/AT (mean PPI of 693 ± 96 ms), as the site 
of the re-entrant substrate was very likely to be situated in the left ventricle, 
particularly for the ischaemic cardiomyopathies. All ICD implants involved lead 
placement at the right ventricular apex. 
Anti-tachycardia pacing was only from the RV electrode in DR ICDs and from 
both the RV and LV leads in BiV devices. The fact that both ventricles were 
paced in patients with BiV defibrillators would not affect the principle of using the 
PPI and PPI-TCL values for VT and AF/AT discrimination. 
 The ROC curves provide an absolute value where a PPI < 615 ms and a PPI-
TCL < 260 ms was more likely to be VT (Figure 8.1.4). However, when reviewing 
the distribution of all recorded PPI and PPI-TCL values, there were areas of 
overlap (Figure 8.1.6). The location of the re-entrant substrate possibly in the 
distant basal-lateral segm nt of the LV may possibly account for this overlap. 
The distance from the pacing source in the RV would therefore approximate 
interval recordings in AT/AF after retrograde invasion of the His-Purkinje system. 
A high attrition rate (33%) was recorded for this data in this study. This was 
because of the strict exclusion criteria that were set in order to maintain the 















Figure 8.1.5  
Representation of entrainment from a pacing site: 
Diagrammatic representation of a pacing site at distance X from a macro- 
re-entrant tachycardia utilizing a critical isthmus. The tachycardia cycle 
length is a sum of limbs A+B+C. 
The post-pacing interval (PPI) would therefore represent 2 x X+ A+B+C as 
the pacing stimulus would need to penetrate the re-entrant circuit and 

















Figure 8.1.6  
Simple linear plots of the absolute PPI and PPI-TCL values for AF/AT and 












 In Figure 8.1.7 A and B, an episode of VT is terminated with a resultant pause 
encroaching within the lower pacing rate of the device. Pacing then continues 
with the sinus rate being tracked with sequential ventricular pacing in a DDD 
mode. Termination of VT and resumption of pacing, even for one beat, were 
regarded as an exclusion from analysis. 
Once a tachycardia is classified as VT or VF and therapy is initiated, and if 
criteria for episode termination are not fulfilled, subsequent therapies may be 
committed. This phenomenon in some manufacturers may be perpetuated and 
even escalate therapies for an originally misclassified rhythm disorder.  
Rapidly conducted AF (Figure 8.1.8) is detected within the VF zone. Anti-
tachycardia pacing in the form of a ramp was unsuccessful in terminating the 
tachycardia, hence the device proceeds to multiple shocks, which also failed to 
terminate the AF initially until the fourth shock resolved the AF to a slower AT or 
sinus tachycardia with conducted ventricular rates below the tachycardia 
detection interval (TDI). The initial ATP as a ramp, is characterised by long PPI 
and the PPI-TCL interval in keeping with a tachycardia with a supraventricular 
origin. This suggests that if these criteria are applied after the initial therapy (ie. 
ATP) as a downstream” discrimination algorithm, they may indeed abort 



















Figure 8.1.7  
Depiction of VT terminated by an ATP burst yielding a falsely long PPI. 
Scatterplot (A) and corresponding intracardiac EGM (B) depicting a burst of 


























Figure 8.1.8  
An episode of rapidly conducted AF into the VT zone resulting in rate 
determined therapy. The ramp ATP before shocks results in a prolonged 
PPI of 660 ms (indicated with an arrow) and a PPI (660 ms)–TCL (316 ms 












At the very least, this concept is fairly intuitive for device specialists when 
evaluating EGMs in patients presenting with shocks in order to decide if they 
were in fact appropriate or not. 
The next obvious application would be in single chamber devices where the 
absence of an atrial lead makes these ICDs more prone to result in ITS, and also 
where it is difficult to interpret the intracardiac EGMs with only ventricular event 
recordings available. This concept is highlighted in Figure 8.1.9. In this figure, an 
episode of VT is entrained from ATP in the form of sequential bursts. The PPI 
intervals after each burst are 380 ms, 400 ms, and 410 ms, with PPI-TCL 
measurements of 80 ms, 100 ms, and 110 ms. These incremental values are 
related to shortening of the coupling intervals (nominally 88%, 81%, and 78%) 
programmed for each burst. On both parameters (PPI < 615 ms and PPI-TCL < 
260 ms), criteria are fulfilled to suggest that this, in fact, is true VT and justifies 
progression to a shock at 22 J, which terminates VT. 
The use of the response to ATP in ICDs has been previously studied by Saba 
and colleagues122;123. Their analysis relied on pacing in both the atria and 
ventricle and they assessed on which chamber the earliest return of tachycardia 
was recorded in order to differentiate an SVT from VT. Furthermore, it was 
proposed as a discriminator for 1:1 A to V tachycardias. This study differs, in that 
discrimination of SVT vs VT is reliant only on a single ventricular lead, making it 
applicable to single chamber devices as well. It also helps differentiate N:1 



























Figure 8.1.9  
Scatterplot with only V EGMs in a single chamber device. The chamber of 
origin of the tachycardia is uncertain, as there is no atrial EGM available. 
Burst ATP “entrains” VT without termination of the VT. The PPI (indicated) 
after each burst, is relatively short at 380 ms with a PPI-TCL (380–300) of 














The use of the PPI and PPI-TCL is reliant on the pause that is noted following 
concealed retrograde penetration of the AVN, specifically in the case of AF/AT. If 
a retrograde AV block existed, this would be a caveat to interpretation of these 
parameters. Furthermore, this study is not intended to differentiate re-entrant 
SVTs viz. AV re-entrant and AV nodal re-entrant tachycardias, which may also 
account for 1:1 tachycardias and can be difficult to differentiate from VT with 
retrograde conduction124;125. This study evaluated the pause interval post ATP 
primarily for diagnosis and not the electrogram response. Other studies have 
shown the diagnostic usefulness of the EGM response post ATP such as a 













The PPI and PPI-TCL difference are established electrophysiological concepts 
that indicate proximity of a pacing site to the source of a tachycardia. This 
concept was applied to differentiate VT from AT/AF showing significant 
differences in the mean values for both these tachycardia sources when 
identified in DR and BiV ICDs. Although this concept was proven in devices with 
pre-existing atrial leads, it has potential application as a discriminator in single 
chamber ICDs with or without morphologic discriminators. It also allows device 
specialists an additional modality to help interpret difficult ICD derived EGMs 
when deciding if the delivered therapy was appropriate or not. It has the potential 
to be incorporated into future device algorithms as a downstream application to 
re-evaluate the result of the ATP to avoid progression to a shock or committed 
therapies in the case of ITS for AF/AT. This concept needs further evaluation in a 
larger prospective study. 
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8.2 An Analysis of Inappropriate Therapies in Implantable Cardioverter 
Defibrillators and Measures to Reduce this Deleterious Effect. 
Introduction 
Inappropriate therapies from ICDs lead to significant morbidity either from the 
painful delivery of shocks and from the pro-arrhythmic potential, which includes 
inappropriately delivered ATP127. Prior studies suggest that 15–28% of anti-
tachycardia therapies may be inappropriate113. Measures to reduce inappropriate 
shocks, including an empiric ablative strategy, have been shown to reduce the 
morbidity128. It seems intuitive that device specialists should also refine ICD 
programming to minimise ITS as this is a less invasive option. 
These ITS occur more frequently in patients having supraventricular arrhythmias, 
particularly atrial fibrillation, or in younger patients who achieve higher sinus 
tachycardia rates129. The use of dual chamber devices does improve the 
algorithmic differentiation of atrial from ventricular arrhythmias but does not 
completely resolve the problem130. I evaluated here the burden of ITS affecting a 
heterogeneous population of recipients of ICDs with DR or BiV defibrillators with 













This was a single centre retrospective analysis. We examined the overall burden 
of ITS (ATP/shock) in a cohort of 250 patients implanted with DR and BiV ICDs 
for both primary and secondary indications over a 23-month follow-up period. 
Patients without atrial leads were excluded from the analysis. Patients with ITS 
due to oversensing or detection of non-physiological factors such as “noise” were 
also excluded from the analysis. This study was therefore streamlined to 
evaluate the use of ICD programming to discriminate SVTs from VT/VF primarily. 
Patients with Medtronic (MN, USA) ICDs: InSynch Sentry, Virtuoso, and later 















In total, 165 DR and 85 BiV were implanted. Thirty-nine episodes were identified 
in 20 patients, yielding an event rate of 8% (20/250) over a 23-month period with 
an average of 1.69 episodes per month (39 episodes/23months) for the whole 
cohort.  
The demographics of patients receiving therapies (ATP and/or shocks) are listed 
in Table 8.2.1. Of these patients, 4 had devices implanted for a primary 
indication, while the remaining 16 patients who received therapies had ICDs 
implanted for a secondary indication. The types of devices were equally 
distributed with n = 2 DR and n = 2 BiV in the primary indication group and n = 8 
DR and n = 8 BiV in the secondary indication group. 
 All patients (n = 4) implanted for a primary indication had ITS for a SVT (AF/AT) 
while 43% (7/16) of patients implanted for a secondary indication had ITS. The 
remaining 56% (9/16) in the secondary indication group had an appropriate 
therapy for VT. The overall incidence of ITS delivered was 4% (11/250 patients) 
in the population (Table 8.2.2). 
The records on all patients who received therapies, appropriate or not, were 
examined. In total, there were 76 sequences of anti-tachycardia pacing (ATP) 
and 44 shocks delivered. Twenty-six ATP sequences (34%) and 16 (36%) 
shocks were inappropriate. All but one patient had advanced discriminators (PR 












The supraventricular tachycardias were classified as AT if the atrial EGMs 
appeared to be regular and as AF if a disorganised and rapid atrial rate (< 200 
ms) was recorded. A PSVT (either AVNRT/AVRT) was inferred depending on the 
response to ATP (VAV vs VAAV response) or termination of SVT without 
entrainment of the atrium with ATP delivered in the ventricles126. The 
















      No. Indication sex age Device Dual/BIV Episode 
       1 Secondary F 78 Virtuoso Dual PSVT 
       2 Secondary M 76 Virtuoso Dual AF 
       3 Primary M 62 Virtuoso Dual AT 
       4 Secondary M 75 Virtuoso Dual VT 
       5 Secondary F 75 Virtuoso Dual VT 
       6 Secondary M 82 Virtuoso Dual VT 
       7 Secondary M 55 Virtuoso Dual VT 
       8 Secondary M 80 Virtuoso  Dual VT 
       9 Secondary M 73 Virtuoso Dual PSVT 
       10 Primary M 62 Concerto BiV AF 
       11 Primary Unknown   Virtuoso Dual AF 
       12 Primary Unknown   Concerto BiV AT 
       13 Secondary M 72 InSync Sentry BiV AT 
       14 Secondary M 72 InSych Sentry BiV AF 
       15 Secondary F 70 InSynch Sentry BiV VT 
       16 Secondary F 81 InSynch Sentry BiV VT 
       17 Secondary M expired 70 InSynch Sentry BiV VT 
       18 Secondary M expired  73 InSynch Sentry BiV AT 
       19 Secondary M expired 78 InSyn Sentry BiV VT 
       20 Secondary M expired 81 InSync Sentry BiV AT 

















Sequence ventricular CL ATP delivered ATP VT zone ATP FVT zone ATP VF zone 
400-370ms 320-240ms 320-300ms
1 330 y Burst
2 310 y Burst during charge
3 370 y Burst 
4 370 y Burst 
5 370 y Burst
6 250 y Burst during charge 
7 350 Y Burst 
8 340 Y Burst  
9 350 y Burst
10 350 y Burst
11 350 y Burst 
12 350 y Burst 
13 280 y Ramp 
14 370 y Burst 
15 370 y Burst 
16 370 y Burst 
17 370 y Burst
18 360 y Burst 
19 360 y Burst 
20 360 y Ramp 
21 370 y Burst 
22 370 y Burst 
23 380 y Burst 
24 380 y Burst  
25 380 y Ramp 
26 390 y Burst  
 
Table 8.2.2 
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Table 8.2.3 















Implantable defibrillators have improved survival in patients at risk of sudden 
cardiac arrhythmia131;132. They have also impacted on the quality of life for 
patients with heart failure133. Despite advances in ICD development and 
advanced programming, ITS have not been fully overcome. These are also more 
common in younger individuals because of sinus tachycardia rates approaching 
the tachycardia detection intervals, as well as in patients with supraventricular 
arrhythmias, predominantly AF134. The delivery of inappropriate shocks has been 
linked to decreased survival and increased morbidity and measures to reduce 
this phenomenon are imperative135. 
Advanced discriminators in Medtronic devices (termed “PR logic”) have been 
demonstrated to have a positive predictive value of 95.2% when therapy is 
delivered (Medtronic, MN, USA literature on Gem III DR ICD). The study cohort 
consisted exclusively of patients with Medtronic dual or BiV ICDs. Patients with 
plugged atrial ports were xcluded to allow for all elements of the discriminatory 
algorithm to be selected. Only one patient did not have additional discrimination 
parameters engaged, making evaluation of standard programming possible. This 
would account for the relatively low (4% or 11/250 patients) incidence of ITS in 
the population studied136. 
The study population entailed a cross section of patients, with a predominance of 
patients with secondary indications for ICD implantation (80%) while the 












primary indication for an ICD received therapies. All of them were delivered 
inappropriately with EGM analysis revealing underlying AF or AT.  
This is keeping with prior data showing a higher incidence of ITS in patients 
having an ICD for a primary indication137. The 16 patients in the secondary 
indication arm that received therapies had a 43% incidence of ITS, again 
characterised by inappropriate classification of AF/AT with 1 suspected PSVT. 
 Anti-tachycardia pacing was the initial therapy in all episodes whether it was 
classified as VT or a SVT. This regimen was a product of the PainFREE Rx II 
study protocol67. This would allow for at least one burst of ATP even in the VF 
zone in order to terminate fast VT during a capacitor charge to obviate the need 
for a shock if the former was ineffective. The categorisation of ITS was therefore 
based on delivery of ATP rather than shock in this study to increase the detection 
rate of these episodes. This, however, does not mean that ATP is innocuous. 
The delivery of rapid ventricular pacing may well be pro-arrhythmic, particularly in 
the population served given the likelihood of an underlying macro re-entrant 
substrate138. 
Ultimately, there were 44 shocks delivered with 36% (n = 16) of these delivered 
for an SVT. However, 6 episodes of ATP succeeded in terminating the SVT. This 
may be understandable if the ventricle was integral in maintaining the 
tachycardia or if advancement of the atrium occurred in a case of termination of 












The latter may presumably have been a consequence of retrograde penetration 
of the AVN, thus slowing conduction to the ventricle and subsequently reducing 
the conducted rate to below the tachycardia detection interval (TDI) of the device.  
 In the case of true VT, ATP successfully terminated VT in 33% (14/28) of cases 
with 67% (28/42) eventually requiring a shock. 
Programming measures that may reduce the risk of an ITS include: 
1. Programming a higher TDI in patients with AF/AT or in the case of 
younger patients receiving ICDs where a higher intrinsic sinus rate may be 
anticipated. 
2. Avoid programming ONSET and STABILITY discriminators as these tend 
to require fewer detection intervals to evaluate a rhythm, therefore 
dominating over other more sensitive algorithms thus increasing the 
chance of ITS. 
3. Programming a slower VT detection interval with advanced discriminators 
so even if an inappropriate shock is delivered it is synchronised to a R 
wave and thus there is less chance of ventricular arrhythmia induction. 
4. If a VT zone is considered, advanced discriminators should be applied to 
overlap into the VF zone. This is referred to as the “SVT limit” in Medtronic 
devices and although this was nominally 320 ms in the above-mentioned 
devices, the current standard is an application of “PR Logic” discrimination 












Therefore, there may be a place for patient-tailored device programming to 
minimise the risk of ITS in those at risk of this phenomenon. We do not discount 
the fact that for the remaining population receiving ICDs, there is merit in an 
empiric programming regimen139. 
Limitations 
The small population size studied makes it difficult to make recommendations on 
intervention. However, the low incidence of ITS in this cohort validates the 
effectiveness of the programming measures we adopted in these patients. 
Conclusion 
The burden of ITS in the population of patients receiving ICDs was 4%, 
significantly lower than in other studies. This may be a consequence of the 
presence of atrial leads in all patients and of rationalised programming criteria 
including having advanced discriminators on. In addition there was a 
predominance of patients with secondary indications for ICDs as those with 
primary indications have a higher incidence of ITS.  
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Implantable defibrillator technology has evolved dramatically and indications 
have expanded. However, battery longevity, device volume, and the pursuit of 
painless therapies remain subjects for further investigation. 
Defibrillator therapies were evaluated in this work on two levels. Given the need 
for multiple VF inductions and defibrillations to assess novel, waveform, and 
vectoral configurations, these studies were conducted in a porcine model. The 
porcine cardiac structure is similar to man and has been used in prior 
defibrillation studies, given its resilience to multiple shocks. At the same time 
however, there are obvious thoracic shape differences, namely a more rounded 
diameter in the pig vs. the reduced antero-posterior diameter seen in man. In 
addition, the cardiac longitudinal axis in the pig faces more anteriorly towards the 
sternal midline as opposed to a left and inferior orientation in humans. These 
factors undoubtedly contributed to outcomes in these experiments, particularly 
for subcutaneous defibrillation configurations. 
The clinical chapters dealt with the utility of ATP for SVT and VT discrimination 
as well as evaluated the overall burden of ITS in a typical clinical cohort. These 
two factors remain topical and challenging despite advances with algorithm 
development for rhythm discrimination. 
In Chapter 4.1. I examined the effect of a preshock delivered endocardially 
before a standard, definitive biphasic shock from a serial capacitance and single 












Other studies have looked at delivery of a preshock from epicardial sites and 
from within the middle cardiac vein. This study was designed to evaluate the 
prototype device as well as to investigate the effect on DFTs. The monophasic 
preshock and biphasic shock were delivered with a similar Can(+) > RV(-) 
polarity at ISIs of 16, 31, and 47 ms.  
No significant differences in DFTs were obtained, but equivalent DFTs were 
noted with the 16 ms ISI, and a trend to increasing DFTs with the higher ISIs. 
The mechanism by which the subthreshold preshock may influence DFTs was 
postulated to prolong the ensuing ISW, allowing the biphasic definitive to be 
delivered into the period of electrical quiescence thus preventing the re-initiation 
of VF. However, this did not translate into overall DFT reduction. A limitation of 
this study was that the ISI were arbitrarily programmed into the prototype device 
and based on prior optical mapping studies that defined the duration of the ISW. 
Given the nominal energy delivery contained within the preshock (2.0–9.6 J 
delivered in a 1:2 ratio with the biphasic shock), the actual ISW after the 
preshock may have been smaller than previously defined. This was evaluated as 
a limitation of this study. 
Recent data have suggested that the convention of having the RV electrode as 
cathodal during the first phase of a shock waveform may be deleterious. An 
anodal configuration allows implosion of colliding defibrillating, high voltage 
wavefronts in the virtual electrode around the RV lead. The second experiment in 












defibrillation efficacy while keeping the optimal ISI evaluated in the preceding 
chapter fixed at 16 ms. 
The prototype defibrillator was again employed to deliver the sequential shock 
waveform and it allowed manipulation of the preshock waveform polarity through 
its custom software (elaterm, Ela-Medical, Sorin Group, France). No significant 
reduction in DFTs occurred with inversion of preshock polarity. This may in part 
be explained again by the nominal energy delivery from the preshock, which has 
not affected a critical mass of myocardium in order to influence significant 
outcome differences. In addition, the duration of the subsequent ISW may not 
have been influenced by polarity change.  
In a clinical setting, patients with high DFTs may have additional electrodes 
implanted in extracardiac sites but it is not known if just adding an additional RV 
defibrillator electrode would be beneficial. In Chapter 5, two 7F narrow diameter 
RV defibrillator leads were placed at an RV apical and at RVOT+RV apical sites 
to evaluate both these options as the combined MES against the conventional 
RV apical lead placement strategy. The MES obtained an overall 25% reduction 
in DFT, but 22% (2/9) of studies yielded equivalent DFTs. The MES strategy is 
therefore a feasible option when faced with high DFTs. Furthermore, the use of 
newer generation 7F lead technology allows greater ability to position defibrillator 
leads onto the RV septum and helps to minimize obstruction to venous flow and 












Subcutaneous ICD systems have become topical particularly in the paediatric 
population. Here, TDF was evaluated against a conventional EDF strategy 
(Chapter 6.1). Transthoracic defibrillation, using a precordial subcutaneously 
implanted ICD with a posteriorly located SQA, consistently defibrillated all 
subjects, and was significantly higher than EDF. Further, TDF was dramatically 
influenced by marginal increments in the weight of the animals, suggesting that 
higher energy devices should be a consideration when implanting a 
subcutaneous ICD system. 
The optimal transthoracic lead and ICD position has not been determined and 
clinical implants have entailed ICD placement in the mid axillary line with an array 
placed in the parasternal region. The result is aesthetically poor and potentially 
restrictive to upper arm motion. Chapter 6.2 deals with varying ICD and SQA 
positions to obtain the optimal TDF configuration. A left precordial ICD Can 
position with a single SQA array positioned around to the posterior thoracic wall 
proved as effective as combining two SQAs also in this posterior thoracic 
location. Minor vectoral variation by separation of the posteriorly placed SQA 
arrays that widened the shock vector to interpose more cardiac tissue between 
the precordial ICD and the SQAs did not influence DFT outcomes. This implies 
than the single SQA and ICD is an adequate subcutaneous system, and 
minimizes implantation time and the amount of surgical intervention required to 
place multiple SQAs. 
In the preceding chapter, the addition of a posterior SQA, essentially increased 












extended beyond the ICD Can to add a short experimental15 cm SQA to the right 
parasternal position, and this was inserted into the SVC port of the ICD. This, 
however, resulted in a mean rise of 4.7 ± 3.3 J in DFTs, and 4/6 cases had a 
DFT ≥ 30 J. This impaired DFT may be explained by current shunting between 
the ICD and the SQA, which also accounts for the significant drop in shock 
impedances. 
The final animal experiment in this manuscript was a pilot project showing the 
feasibility of percutaneous delivery of an SVC defibrillation electrode into the PPS 
and then assessing DFTs using a precordial and subcutaneously placed ICD vs. 
a conventional endocardial RV apical electrode vs. a subcutaneous ICD system 
with a single subcutaneous ICD placed posteriorly around the chest wall. The 
electrode placement into the PPS was safely performed but DFTs proved 
equivalent to the subcutaneous system. 
In the clinical chapters, painless ICD therapy namely, ATP was evaluated as a 
discriminator to differentiate AF/AT from VT. This was evaluated in dual chamber 
ICDs for proof of concept, but its application is intended for single chamber 
devices where the absence of atrial electrograms can make rhythm 
discrimination difficult. 
The pause after ATP that fails to terminate or significantly perturb the tachycardia 
cycle length was then evaluated. The pause after ATP until the return of the 
sensed tachycardia on the ventricular channel, described as the PPI was 












PPI-TCL difference < 260 ms predicted VT, and higher values suggest AF/AT as 
the mechanism of arrhythmia. 
Inappropriate ICD therapy delivery remains a substantial problem. Analysis of a 
typical heterogeneous cohort of 250 patients revealed an event rate of 8% of ICD 
therapies over a 2-year follow-up period. Half of these therapies (4%) were 
inappropriate for AF/AT. This was significantly lower than other quoted studies, 
but reflects a selection bias and the fact that physician tailored therapy zone 












10. Future Directions 
Myocardial dysfunction increases the risk of sudden cardiac death, but the 
predominant clinical manifestation is heart failure. Device-based therapy in the 
form of cardiac resynchronization is used as adjunctive management in eligible 
patients and is frequently coupled with ICD therapy. 
Defibrillation from an electrode within the coronary sinus has shown promise, 
yielding reduced DFTs. The ICD Can has always been included in these studies 
Therefore, it seems reasonable to assume that if the left ventricular pace/sense 
lead that was being deployed within a coronary sinus branch was capable of 
incorporating a high voltage defibrillation electrode, it would be conceivable to 
deliver a shock from the left ventricle as well. Taking this a step further, if the ICD 
and SVC electrodes were programmed out of the circuit and the shock vector 
was maintained merely between the RV and LV electrodes, and then bystander 
non-cardiac tissue from the thorax could be excluded from the shocking circuit. 
This may result in lower impedance to the shock and greater current delivery to 
the ventricular myocardium. This may translate into lower DFTs and possibly 
minimise pain from the shock by eliminating pain-sensitive structures from the 
defibrillation circuit. 
Thus biventricular defibrillation may therefore be included as a programmable 
option in new generation ICDs. The LV lead position from effective CRT is 












entrant substrate in ischaemic aetiologies. This makes ATP from the LV lead 
effective, as it is delivered closer to the re-entrant circuit. Therefore, delivery of 
the shock closer to the scar may be more efficacious. 
Fibrillating myocardium represents heterogeneous regions of depolarization and 
repolarisation. The depolarising wavefront from a delivered shock may encounter 
regions of myocardium that are refractory, making the activation here 
superfluous. If a sub-threshold high frequency burst of alternating current such as 
that which is used to induce VF in the ICD is delivered just prior to delivery of the 
shock, this may serve to homogenise the overall myocardial charge prior to 
shock delivery this reducing DFTs. This would, however, require specific 
calibration of the ICD to deliver this discharge from a single device else a serial 
arrangement of two ICDs with timed delivery would be required to achieve this 
sequential discharge. 
The PPI and PPI-TCL parameters that have been shown to help discriminate 
AF/AT and VT in the clinical cohort studied here need to be validated in a larger 
population. It has the potential to be incorporated as a downstream discrimination 
algorithm post-delivery of ATP. This will help differentiate inappropriate from 
appropriate ATP delivery and abort progression to a shock, if deemed 
inappropriate. This potentially will avoid painful discharges and reduce 
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